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Imatinib mesylate (Gleevec, Glivec) is a rationally designed tyrosine kinase 
inhibitor, originally created to target Bcr-Abl in chronic myelogenous leukemia 
(CML). This synthetic small molecule was subsequently found to have activity in 
gastrointestinal stromal tumors (GIST) against c-kit and is now approved for both 
indications worldwide. Clinical studies are currently underway to evaluate imatinib 
in a range of additional malignancies. 
Initial clinical response to imatinib was extremely promising. In addition to 
impressive results in chronic-phase CML (one study reported complete 
hematological and cytogenic responses in 95% and 74% of patients, respectively), 
imatinib was shown to significantly improve the previously poor prognosis of 
individuals with unresectable or metastatic GIST [1,2]. Unfortunately, along with 
primary resistance noted in patients with advanced CML, acquired resistance to 
imatinib developed in a number of individuals. Numerous mechanisms of 
resistance have been identified, many of which involve genetic changes in Bcr-Abl 
or c-kit. However, it has also been suggested that decreased plasma concentrations 
of imatinib, leading to sub-optimal tumor cell exposure, may also be contributing 
[3]. 
 Imatinib is typically administered once daily as an oral tablet and exhibits 
very high bioavailability (98%) [4]. Though the pharmacokinetics of this agent are 
considered to be linear over a wide dose range, substantial interindividual 
variability has been observed in many studies, yet remains largely unexplained. 
The aim of the work described in this thesis was to not only improve 
understanding of the factors affecting the pharmacokinetic variability of imatinib in 
patients with cancer, but to determine whether these factors might be contributing 
to pharmacokinetic resistance and assess strategies for overcoming this.  
This research was initiated following the identification of imatinib as a substrate 
for both ABCB1 (P-glycoprotein) and ABCG2 (BRCP) [5,6]. The role of these 
polymorphic transporters as mechanisms of resistance to anticancer drugs is 
reviewed in Chapter 2.  
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Imatinib is highly metabolized by Cytochrome P450 isozymes 3A4 and 3A5, 
both of which are polymorphic [4]. Midazolam, a sedative, can be used as a 
phenotyping probe to assess CYP3A4 and CYP3A5 activity in vivo [9]. Chapter 3 
describes the method development and validation of an analytical assay to measure 
midazolam concentrations in human plasma. Chapter 4 evaluates the impact of 
polymorphisms in CYP3A4 and CYP3A5 on the activity of the encoded enzymes in 
patients with cancer, by determining the correlation between midazolam 
pharmacokinetics and genotype.  
Combining anticancer agents with inhibitors of transporter proteins has been 
tested clinically for substrates of ABCB1 and remains of interest for modulation of 
tumor exposure to substrate drugs. We hypothesized that addition of an ABCG2 
inhibitor to an imatinib treatment regimen may increase in vivo drug exposure 
(through decreased drug efflux in the gut and liver) and potentially modulate brain 
penetration, due to the expression of ABCG2 on endothelial cells in the brain. 
Chapter 5 evaluates the pharmacokinetic effect of administering tariquidar, an 
inhibitor of both ABCB1 and ABCG2, prior to oral treatment with imatinib in mice.  
Judson et al. reported on the clinical observation that drug clearance appeared 
to increase with chronic drug treatment, suggesting that imatinib may be inducing 
its own efflux or metabolism [10]. Burger et al. subsequently demonstrated an 
upregulation of both ABCB1 and ABCG2 in Caco-2 cells that were treated 
chronically, leading to increased drug efflux [11]. In Chapter 6, the effect of 
chronic imatinib treatment on plasma pharmacokinetics and the expression of 
these transporters was evaluated in vivo.   
 A letter by Miyazwa et al. appeared in the International Journal of 
Hematology, questioning whether 400 mg daily imatinib is an optimal starting dose 
of imatinib in Japanese patients, after observing much higher rates of 
thrombocytopenia than had previously been seen in a large multi-center study 
performed in Europe and the US [7]. In contrast, doses of up to 800 mg per day 
have been relatively well tolerated in a number of studies performed in the US [8]. 
These observations further supported the hypothesis that genetic variation could be 
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contributing to the pharmacokinetic variability. In Chapter 7, correlations between 
the pharmacokinetics of imatinib and polymorphisms in a range of transporters and 
enzymes, including ABCB1, ABCG2, CYP3A4 and CYP3A5, were explored in a 
large population of patients with cancer, to determine whether these mutations 
might contribute to the large interindividual variability in imatinib 
pharmacokinetics. 
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Summary 
ATP-binding cassette (ABC) genes play a role in the resistance of malignant cells to 
anticancer agents. The ABC gene products, including ABCB1 (P-glycoprotein) and ABCG2 
(BCRP, MXR, ABCP), are also known to influence oral absorption and disposition of a 
wide variety of drugs. As a result, the expression levels of these proteins in humans have 
important consequences for an individual’s susceptibility to certain drug-induced side 
effects, interactions, and treatment efficacy. Naturally occurring variants in ABC 
transporter genes have been identified that might affect the function and expression of the 
protein. This review focuses on recent advances in the pharmacogenetics of the ABC 
transporters ABCB1 and ABCG2, and discusses potential implications of genetic variants 
for the chemotherapeutic treatment of cancer. 
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Introduction 
Cells exposed to toxic compounds can develop resistance by a number of 
mechanisms including decreased uptake, increased detoxification, alteration of target 
proteins, or increased excretion [1]. Several of these pathways can lead to multidrug 
resistance (MDR) in which the cell is resistant to several commonly used drugs in addition 
to the initial compound to which it was exposed. This is a particular limitation to cancer 
chemotherapy, and cells with an MDR phenotype often display other properties, such as 
genome instability and loss of checkpoint control, that complicate further therapy [1]. The 
ATP-binding cassette (ABC) genes play an important role in MDR, and various genes have 
been identified that are associated with altered anticancer drug transport. These genes 
belong to a large family of transmembrane proteins that bind and subsequently hydrolyze 
ATP, using the energy to drive the transport of various molecules across cell membranes 
[2-4]. 
It is now well established that ABC gene products may also play a major role in 
host detoxification and protection against xenobiotic substances [5]. Indeed, genetic 
knock-outs of murine ABC transporter genes have shown altered blood-brain barrier 
function [6,7], intestinal drug absorption [8,9], fetal drug exposure [10], and drug-induced 
damage to testicular tubules [11], choroid plexus epithelium and oropharyngeal mucosa 
[12]. Furthermore, recent re-sequencing of various human ABC transporters has revealed a 
number of naturally-occurring allelic variants that appear to affect the functional activity 
of the encoded protein in vivo [13-15]. This genetic variation may potentially modulate 
transporter phenotypes in humans and thereby affect their predisposition to toxicity and 
response to drug treatment. This review provides an update on the pharmacogenetics of 
the two best characterized ABC transporters, ABCB1 (P-glycoprotein) and ABCG2 (BCRP, 
MXR, ABCP), and discusses the potential implications of genetic variation of the proteins 
on anticancer drug response in patients. 
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Structural organization of the ABCB1 and ABCG2 genes 
Proteins are classified as ABC transporters based on the sequence and organization 
of their ATP-binding domains, also known as nucleotide-binding folds (NBFs). The NBFs 
contain characteristic motifs (viz. the Walker A and B motifs), separated by approximately 
90–120 amino acids, found in all ATP-binding proteins. ABC genes also contain an 
additional element, the signature (C) motif, located upstream of the Walker B site [16]. 
The functional protein typically contains two NBFs and two transmembrane domains. 
These domains contain 6–11 membrane-spanning α-helices which can form pores for 
allowing molecules through the membrane and therefore dictate substrate specificity. The 
NBFs are located in the cytoplasm and transfer the energy to transport the substrate across 
the membrane. ABC transporters are mostly unidirectional. In eukaryotes, most ABC genes 
move compounds from the cytoplasm to the outside of the cell or into an intracellular 
compartment (e.g., the endoplasmic reticulum, mitochondria, or peroxisome). Most of the 
known functions of eukaryotic ABC transporters involve the shuttling of hydrophobic 
compounds either within the cell as part of a metabolic process or outside the cell for 
transport to other organs or for excretion from the body. 
The eukaryotic ABC genes are organized either as full transporters containing two 
transmembrane domains and two NBFs, or as half transporters. The latter must form 
either homodimers or heterodimers to form a functional transporter. ABC genes are 
widely dispersed in eukaryotic genomes and are highly conserved between species, 
including yeast, indicating that most of these genes have existed since the beginning of 
eukaryotic evolution [17]. The genes can be divided into subfamilies based on similarity 
in gene structure (half versus full transporters), order of the domains, and on sequence 
homology in the NBF and TM domains. There are seven mammalian ABC gene 
subfamilies, and all have standard nomenclature, developed by the Human Genome 
Organization (see: http://www.humanabc.org) [18]. 
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Physiological and pharmacological function 
Two ABC genes appear to account for nearly all of the MDR phenotypes in both 
humans and rodent models, which are selected with natural product cytotoxic drugs in 
vitro and show decreased drug accumulation: ABCB11 and ABCG2 encoding ABCB1 (P-
glycoprotein) and ABCG2 [formerly breast cancer resistance protein (BCRP), 
mitoxantrone resistance protein (MXR), or ABC transporter in placenta (ABCP)], 
respectively. Overexpression of these genes confers resistance to a wide variety of 
hydrophobic natural product drugs [19]. 
Inhibitors of the major ABC genes contributing to MDR have been developed, and 
extensive preclinical and clinical research has been carried out aimed at blocking the 
development of drug resistance during chemotherapy. Moreover, activity of the ABC 
transporter proteins can be blocked with doses of the inhibitor that do not have adverse 
side effects or significantly affect the pharmacokinetic profile of the anticancer drug 
regimen [20,21]. However, early ABCB1 inhibitors have not been very successful at 
reversing MDR in clinical trials, for a variety of reasons, including poor pharmacokinetic 
profiles and the inability to accurately evaluate the effect on ABCB1[22].  
 
ABCB1 
The ABCB1 gene maps to chromosome 7q21.1 and is the best characterized ABC 
drug transporter. It consists of 28 exons and 27 introns. Formerly known as MDR1 or 
PGY1, ABCB1 was the first human ABC transporter gene cloned and characterized 
through its ability to confer an MDR phenotype to cancer cells that had developed 
resistance to certain chemotherapy drugs [23]. The gene product ABCB1 (P-glycoprotein) 
is a 170 kDa, 1280 amino acid protein: two 610 amino acid half-transporters, each 
comprised of one TM and one NBF, joined by a sixty amino acid flexible linker. It has 
been shown to be a promiscuous transporter of a large number of hydrophobic substrates 
from diverse therapeutic classes [15], including several anticancer drugs [24], and its 
                                                
1 Italicized symbols designate genes, alleles or loci to distinguish them from phenotype. All Human Gene 
Mapping designations are capitalized; for genes from other species, the nomenclature committee 
recommendation is given. 
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function can be inhibited by a large variety of chemical compounds (Table 1). The gene is 
expressed in multiple healthy organs, and is thought to play an important role in removing 
toxic substances or metabolites from cells. For example, the protein is highly expressed in 
cells at the blood–brain barrier and presumably plays a role in transport of toxic 
compounds out of the brain, effectively preventing uptake [25]. 
The ABCB1 protein is also expressed in many excretory cell types such as kidney, 
liver, intestine, and adrenal gland, where the normal physiological function is thought to 
involve the secretion of toxic xenobiotics and their metabolites, in addition to steroids [26-
28]. Mice have two closely related homologues of ABCB1, Abcb1a and Abcb1b. Mice 
homozygous for disrupted Abcb1 genes are phenotypically normal but are extremely 
sensitive to certain neurotoxins such as ivermectin [6,7]. These studies led to the 
characterization of an important role of ABCB1 in transport of several agents across the 
blood-brain barrier, since lack of gene expression led to an accumulation within the brain. 
ABCB1 is also highly expressed in hematopoietic stem cells, where it may serve to protect 
these cells from toxic substrates [29,30] and has been shown to play a role in the 
migration of dendritic cells [31]. 
The expression of ABCB1 on the apical surface of epithelial cell of the lower 
gastrointestinal tract (jejunum, ileum, and colon) has been shown to influence intestinal 
drug absorption and limit oral bioavailability of many drugs, including important 
anticancer agents derived from natural sources [28]. This finding has been the starting 
point for various proof-of-concept studies in cancer patients by administering these drugs 
orally in combination with inhibitors of ABCB1 to enhance intestinal drug uptake and 
increase the oral bioavailability [32-34].  
 
ABCG2  
The ABCG2 (formerly BCRP/MXR/ABCP) gene maps to chromosome 4q22 and 
consists of 16 exons and 15 introns [35]. It encodes a 655 amino acid half transporter with 
a NBF-TM orientation [36-38]. Analysis of cell lines resistant to mitoxantrone that did not 
overexpress ABCB1 or ABCC1 led several laboratories in the late 1990s to almost 
simultaneously identify ABCG2 as a gene encoding a drug transporter [39-41]. ABCG2  
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Table 1. Selected Substrates and Inhibitors of ABCB1 and ABCG2 
 
Substrates Inhibitors 
ABCB1 
Actinomycin D [149] Biricodar (VX-710) [150] 
Daunorubicin [151] Cyclosporin A [152] 
Docetaxel [153] Dexniguldipine [154] 
Doxorubicin [155]  GF120918 [156] 
Etoposide [157] JTV-519 [158] 
Imatinib [159] LY335979 [160] 
Irinotecan [161] R101933 [162] 
Mitoxantrone [163] Ritonavir [164] 
Paclitaxel [165] Tariquidar (XR9576) [166] 
SN-38 [161] Valspodar (PSC 833) [167] 
Teniposide [168]   Verapamil [152] 
Topotecan [169]   
Vinblastine [155]   
Vincristine [170]    
ABCG2 
9-Aminocamptothecin [171,172] 17-B-estradiol [64] 
Ciprofloxacin [173] Biricodar (VX-710) [174] 
Daunorubicin [175]  CI1033 [176] 
Diflomotecan (BN-80915) [177] Circumin [178] 
Dipyridamole [179] Cyclosporin A [180] 
DX-8951f [181]  Diethylstilbestrol [182] 
Epirubicin [183]  Elacridar [184] 
Etoposide [100,185] Fumitremorgin C [62] 
Flavopiridol [186]  GF120918 [60] 
Gefitinib [187] Gefitinib [188] 
Heterocyclic amines [55,189] Imatinib [188] 
Homocamptothecin [177]  Ko143 [54] 
Imatinib [190]  Nelfinavir [191] 
J-107088 [192]  Nicardapine [179] 
Methotrexate [100,185]  Nimodipine [179] 
Mitoxantrone [175] Nitrendipine [179] 
NB-506 [192]  Novobiocin [193] 
Norfloxacin [173] Ortataxel [174] 
Ofloxacin [173] Pantoprazole [184] 
SN-38 [194]  Reserpine [195] 
Teniposide [196] Ritonavir [197] 
     Topotecan [198] Rosuvastatin [199] 
     UCN-01 [98] Saquinavir [191] 
  Sirolimus [180] 
  Tacrolimus [180] 
  Tariquidar (XR9576) [98] 
  Tryprostatin A [200]  
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confers resistance to various topoisomerase I and II inhibitors and is amplified or involved 
in chromosomal translocations in cell lines selected with topotecan, mitoxantrone, or 
doxorubicin treatment [42]. It might be expected that ABCG2 functions as a homodimer 
[43], although more recently it was shown that human ABCG2 probably exists as a 
homotetramer with possibly a higher form of oligomerization (Figure 1) [44]. 
 
 
Figure 1. Upper panel, Diagram of generic ABC transporter, showing half-transporter (blue), full 
transporter (blue and green), and the formation of a tetramer. Tubes represent helices through cell 
membrane. Lower panel, Schematic representation of higher order organization of ABCG2, with 
three tetramers grouping together. 
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ABCG2 can also transport several dyes, such as rhodamine 123 and Hoechst 
33342, and the coding gene is highly expressed in a subpopulation of hematopoietic stem 
cells (side population) that stain poorly for these dyes [45-49]. However, the normal 
function of the gene in these cells is not completely understood. ABCG2 is also highly 
expressed in the trophoblast cells of the placenta [39,50]. This suggests that the protein is 
responsible either for transporting compounds into the fetal blood supply or removing 
toxic compounds [8,51]. The gene is also highly expressed in the intestine [52,53], and 
restricts the exposure to ingested carcinogens and potentially toxic xenobiotics by 
decreasing uptake from the gut lumen [51,52,54-56]. Indeed, a food carcinogen present in 
overcooked meat, which has been linked to breast cancer, has been shown to be a 
substrate for ABCG2, providing further evidence of an evolutionary protective function 
[55]. Like with ABCB1, inhibitors of the ABCG2 transporter proteins have been shown to 
be useful in making anticancer substrate drugs orally available [57,58].  
In cells from mice deficient in the Abcb1a, Abcb1b, and Abcc1 genes, exposure to 
mitoxantrone, topotecan, or doxorubicin results in amplification of the Abcg2 gene 
[19,59]. This strongly suggests that ABCG2 is one of three major transporter genes 
involved in drug resistance in mammalian cells. Inhibitors of ABC drug transporters 
represent a potential strategy for preventing the development of drug-resistant tumors 
[21]. Effective inhibitors of ABCG2, including GF120918 and (analogues of) 
fumitremorgin C have been described [42,60-62] (Table 1), and several of these are 
currently being tested clinically in an attempt to reverse resistance to anticancer substrate 
drugs. Recently, ABCG2 expression has been shown to be upregulated by hypoxia, 
through activation of the hypoxia-inducible transcription factor (HIF-1) signaling pathway 
[49]. This might have great implications for cancer, due to the hypoxic conditions that 
exist within tumors. 
ABCG2 also plays a role in the transport of sterols [63]; 17-β-Estradiol is a 
competitive substrate for ABCG2, though it was originally believed to be an inhibitor 
[64], and it also stimulates transcription of ABCG2 [65]. An estrogen response element 
has recently been identified in the 5’ flanking region of the ABCG2 gene. In addition,  
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Table 2. Summary of common genetic variants in the ABCB1 gene 
cDNA 
positiona 
Region Wild-type 
allele 
Variant 
allele 
Amino 
Acid 
Change 
-274 Intron -1 G A   
-223 Intron –1 C T   
-146 Intron –1 T C   
-60 Intron –1 A T   
-41 Intron -1 A G  noncoding 
-241 Exon 1 G A  noncoding 
-145 Exon 1 C G  noncoding 
-129 Exon 1 T C  noncoding 
-43 Exon 1 A G  noncoding 
+140 Intron 1 C A   
+237 Intron 1 G A   
-4 Exon 2 C T  Noncoding 
-1 Exon 2 G A  Noncoding 
61 Exon 2 A G 21 Asn to Asp (N21D) 
-8 Intron 3 C G   
266 Exon 4 T C 89 Met to Thr (M89T) 
-25 Intron 4 G T   
307 Exon 5 T C 103 Phe to Leu (F103L) 
+139 Intron 6 C T   
+145 Intron 6 C T   
548 Exon 7 A G 183 Asn to Ser (N183S) 
729 Exon 8 A G 243 Syn 
781 Exon 8 A G 261 Ile to Val (I261V) 
-44 Intron 9 A G   
-41 Intron 10 T G   
1199 Exon 11 G A 400 Ser to Asn (S400N) 
-4 Intron 11 G A   
1236c Exon 12 C T 412 Syn 
1308 Exon 12 A G 436 Syn 
+17 Intron 12 G A   
+44 Intron 12 C T   
1474 Exon 13 C T 492 Arg to Cys (R492C) 
+24 Intron 13 C T   
1617 Exon 14 C T 539 Syn 
+38 Intron 14 A G   
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+38 Intron 15 G A   
1985 Exon 16 T G 662 Leu to Arg (L662R) 
2005 Exon 16 C T 669 Arg to Cys (R669C) 
-27 Intron 17 A G   
+8 Intron 20 C G   
+24 Intron 20 G A   
+40 Intron 20 C T   
2547 Exon 21 A G 849 Ile to Met (I849M) 
2650 Exon 21 C T 884 Syn 
2677 Exon 21 G T 893 Ala to Ser (A893S) 
2677d Exon 21 G A 893 Ala to Thr (A893T) 
+31 Intron 22 G A   
2956 Exon 24 A G 986 Met to Val (M986V) 
2995 Exon 24 G A 999 Ala to Thr (A999T) 
3151 Exon 25 C G 1051 Pro to Ala (P1051A) 
3320 Exon 26 A C 1107 Gln to Pro (Q1107P) 
3322 Exon 26 T C 1108 Trp to Arg (W1108R) 
3396 Exon 26 C T 1132 Syn 
3421 Exon 26 T A 1141 Ser to Thr (S1141T) 
3435e Exon 26 C T 1145 Syn 
3751 Exon 28 G A 1251 Val to Ile (V1251I) 
3767 Exon 28 C A 1256 Thr to Lys (T1256K) 
4030 Exon 28 G C  Noncoding 
4036 Exon 28 A G  Noncoding 
+21 Intron 28 T C   
1 cDNA numbers are relative to the ATG site and based on the cDNA sequence from GenBank 
accession number M14758 with an A as the reference at position 43. 
b The location of the variants in the DNA sequence is indicated as intronic or non-coding; intron -1 is 
the intronic sequence immediately preceding exon 1. The amino acid position is indicated for those 
variants in the coding exonic sequence. The addition Syn indicates a synonymous nucleotide 
change, so the resulting protein is unchanged. 
c Also referred to as ABCB1*8 [76]; d Also referred to as ABCB1*7 [76]; e Also referred to as ABCB1*6 
[76] 
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testosterone and tamoxifen have all been shown to stimulate ATPase activity, similar to 
estradiol [66]. 
 
Genetic variants of the ABCB1 and ABCG2 genes 
ABCB1 variants 
With respect to the ABC transporters, genetic variations of the human ABCB1 gene 
have been most extensively studied. Several recombinant variants have been generated 
either by in vivo drug selection or by site-directed mutagenesis techniques, which show 
altered substrate specificity or impaired function of a properly assembled protein [24,67]. 
Hoffmeyer et al. were the first to report a systematic screen of the ABCB1 gene for the 
presence of single-nucleotide polymorphisms (SNP) [68,69]. The original ABCB1 
sequence was defined as wild-type and all 28 exons, including the core promoter region 
and exon-intron boundaries, were sequenced. Sequencing the ABCB1 genes from 188 
Caucasian volunteers revealed 15 polymorphisms (in 8 exons and 7 introns), of which 3 
had been described previously. A summary of the various commonly observed SNPs and 
insertion/deletion (indel) polymorphisms in the ABCB1 gene is provided in Table 2 [70-
73].  
A detailed analysis of the potential functional consequences of different ABCB1 
variants has not yet been performed, except for five most common non-synonymous 
coding SNPs (i.e., Asn21Asp, Phe103Leu, Ser400Asn, Ala893Ser/Thr, and Ala998Thr) as 
assessed by a vaccinia virus-based transient expression system [74]. Transport studies of 
several tested substrates indicated that the substrate specificity of the protein was not 
substantially affected by any of the SNPs, whereas cell surface expression and function of 
even double mutants showed no difference from the wild-type protein. This suggests that 
these SNPs result in mutant proteins with a cellular distribution and function similar to the 
wild-type protein. One of the tested SNPs, the ABCB1 2677G>T/A [75] contains a tri-
allelic polymorphism (with G at nucleotide 2677 found in the wild-type sequence, and 
with A or T at that position being the two possible variants), which results in an amino 
acid change in exon 21 (Ala893Ser/Thr). However, work by others has shown that the 
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Ser893 substitution is associated with an altered MDR pattern in AdrR MCF-7 cells as well 
as approximately 2-fold enhanced efflux transporting ability in stably transduced NIH3T3 
GP+E86 cells [76]. These disparities between the studies might reflect differences in the 
substrates used in these assays, in intrinsic transporter function in the various expression 
systems, or in the ABCB1 haplotypes that were heterologously expressed [73]. It is of note 
that most of these studies have not addressed the possibility that changes in expression of 
the encoded protein can have a greater influence on function than changes in transport 
activity itself. Clearly, further work is required to evaluate these contradictory findings 
regarding the ABCB1 2677G>T/A polymorphism with stratification according to common 
haplotypes. 
The most extensively studied ABCB1 variant to date is a common synonymous 
mutation at the transition C to T at position 3435 (3435C>T) at a wobble position in exon 
26. Although this transition does not change its encoded Ile amino acid (i.e., a silent 
mutation), it is the only ABCB1 variant identified thus far that may be associated with 
altered protein expression in different human tissues (Table 3). Greiner et al. first evaluated 
the expression of ABCB1 in duodenal biopsies of 21 subjects, and Hoffmeyer et al. 
subsequently identified a 2-fold decrease in protein level (P = 0.056) for individuals with 
the homozygous T allele (TT genotype) as compared to those with the wild-type alleles 
(CC genotype) [68,77]. In addition, it has been shown that rhodamine 123 fluorescence in 
CD56+ natural killer cells was significantly lower (i.e. greater efflux) in individuals with the 
CC genotype (51.1 ± 11.4%; n = 10) compared to those with the TT genotype (67.5 ± 
9.5%; n = 11) [78]. The TT genotype also led to a decrease in ABCB1 mRNA level in this 
study, as compared to the CC genotype. Despite the silent nature of this SNP, it is also 
possible that the T allele produces an Ile codon that is infrequently utilized in the human 
genome, leading to reduced translation efficiency. Alternatively, changes in ABCB1 
expression and function in individuals homozygous for the TT genotype by other, yet 
unknown causes might have been incorrectly attributed to the synonymous change at this 
position. Differences in protein expression and function might also result from other non-
coding and intronic nucleotide changes that are in phase with the ABCB1 3435C>T 
polymorphism. Nonetheless, the association of the 3435C>T polymorphism with ABCB1 
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protein expression and function remains controversial. In fact, various investigators have 
reported that the T allele is associated with increased protein expression or has no clearly 
discernible effect (Table 3). This degree of variability observed in the various studies might 
also reflect the ethnic haplotype diversity in the population samples [73]. However, many 
of these studies have used different methodology for determination of protein expression, 
which may be a contributing factor. Additionally, expression of ABCB1 is known to be 
regulated by the pregnane X receptor, a ligand-activated, nuclear receptor, which may 
further obscure any effects of the polymorphism [79,80]. More recently, Takane et al. have 
identified novel variants in the promoter region of the ABCB1 gene with increased 
transcriptional activity and mRNA expression in the placenta [81]. However, because the 
frequency of these variants in the Japanese and Caucasian populations is very low, further 
studies are required to establish their impact on drug absorption and disposition as well as 
response to treatment. 
 
ABCG2 variants 
In contrast to the extensive investigations into the pharmacological significance of 
ABCB1 SNPs, surprisingly little has still been reported regarding naturally-occurring 
variants in other ABC transporter genes [82]. To date, ABCG2 has been systematically 
screened for genetic variations in 13 different ethnic groups [83-90], and various genetic 
variants have been identified (Figure 2 and Table 4). The common ABCG2 421C>A allele 
in exon 5, in which the C to A transversion results in an amino acid change of Gln to Lys 
at codon 141 has been associated with low ABCG2 expression levels [50,85,91-93] as 
well as increased sensitivity to several anticancer drugs in vitro as compared to the wild-
type protein, due to decreased efflux from the cells [85]. This allele is carried by 46% of a 
normal Japanese population [85]. Interestingly, this SNP has been found in African-
Americans and Africans from North or South of the Sahara at only very low frequencies or 
not at all, as illustrated in Table 5 [86,87]. In addition to the possible decrease in 
expression levels, ATPase activity in the ABCG2 421C>A mutant has been shown to be 
significantly lower than with wild-type ABCG2 [89,94]. 
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Table 4. Summary of genetic variants in the ABCG2 gene, occurring in humans 
 
Position in 
genea 
Nucleotideb Region Wild-
type 
allele 
Variant 
allele 
Amino 
Acid 
Change 
-39141  5’Flanking region CTCA -  CTCA deletion 
-20445  5’ Flanking region C T   
-20296  5’ Flanking region A G   
-19781  5’ Flanking region A G   
-19202  5’ UTR G C   
-18845  5’ UTR T C   
-18604  5’ UTR A -  deletion 
-18482 -113 Exon 1 C T  noncoding 
-18398 -29 Exon 1 A G  noncoding 
34 34 Exon 2 G A 12 Val to Met (V12M) 
114 114 Exon 2 T C 38 synonymous 
239  Intron 2 A G   
7268  Intron 2 T C   
7491  Intron 3 - T  insertion 
8007  Intron 3 G A   
8184 369 Exon 4 C T 123 synonymous - (wobble) 
8191 376 Exon 4 C T 126 Gln to Term (Q126Stop) 
8253  Intron 4 G C   
8825 421 Exon 5 C A 141 Gln to Lys (Q141K) 
8878 474 Exon 5 C T 158 synonymous 
8883 479 Exon 5 G A R160Q  
18186  Intron 5 A G   
18286 616 Exon 6 A C 206 Ile to Leu (I206L) 
21540  Intron 6 C T   
21903  Intron 7 A G   
26297 1098 Exon 9 G A 366 synonymous 
32367  Intron 9 A T   
32604  Intron 10 T A   
38369  Intron 10 A G   
38398 1291 Exon 11 T C 431 Phe to Leu (F431L) 
38429 1322 Exon 11 G A 441 Ser to Asn (S441N) 
38485  Intron 11 A G   
40121  Intron 11 G A   
40303 1425 Exon 12 A G 475 synonymous 
40343 1465 Exon 12 T C 489 Phe to Leu (F489L) 
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40408  Intron 12 G A   
40417  Intron 12 A G   
40419  Intron 12 G T/C   
42127 1515 Exon 13 C - 506, 
507, 
508, 
509 
Frame shift: F506S, F507L, 
V508L, M509stop 
42289  Intron 13 C T   
42314  Intron 13 T G   
44061  Intron 13 A T   
44072  Intron 13 C T   
44168 1723 Exon 14 C T 575 Arg to Term (R575Stop) 
44997  Intron 14 A G   
45073 1768 Exon 15 A T 590 Asn to Tyr (N590Y) 
47355 1858 Exon 16 G A 620 Asp to Asn (D620N) 
 2332 3’ UTR A TA   
 2364 3’ UTR A C   
  2512 3’ UTR C T     
a Position with respect to translation start of ABCG2 gene. (GenBank accession number, AC084732) 
b From mRNA, (GenBank accession number, XM_032424)    
c Syn denotes a synonymous nucleotide change, so the encoded protein remains 
unchanged.  
 
An additional potentially functional polymorphism has been identified in the 
ABCG2 gene at nucleotide position 34 resulting in a V12M amino acid change. All 
Mexican-Indians screened possessed at least one variant allele, while the frequency in 
Caucasians was only 4.7% [86]. It is believed that this mutation results in poor 
localization of the ABCG2 protein and a subsequent decrease in efflux from the cell [85].  
A mutation at the arginine on amino acid position 482 in human cancer cells 
expressing ABCG2 or mouse cells expressing Abcg2 has been shown to have a crucial 
role in protein function and in altering the MDR phenotype by changing substrate 
specificity [95-98]. Interestingly, this mutation has never been seen in individuals [83,95-
97,99]. Cell lines carrying this variant have been shown to have altered substrate 
specificity; e.g. mitoxantrone is transported by both wild-type and variant ABCG2. 
However, cells expressing either the R482G or R482T mutant both demonstrated greater 
resistance to mitoxantrone than the wild-type, suggesting that the mutant is a better 
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transporter for this agent [97]. In contrast, the anticancer drug methotrexate is transported 
by wild-type ABCG2, but not by either mutant [99,100], whereas daunorubicin is 
transported only by the mutant ABCG2 protein. 
 
Phenotype-genotype relationships 
Variation in the pharmacokinetic behavior of an anticancer drug in a patient population is 
the net result of complex interactions between genetic, physiological, and environmental 
factors. It is reasonable to assume that genetic variations in ABC transporter genes could 
alter drug disposition and might have clinical consequences. If the function or expression 
level of interstitial ABC transporters is altered due to genetic changes, intestinal secretion 
of substrate drug into the gut lumen may change. Such information may be valuable in 
predicting a change in bioavailability of orally administered substrate drugs in individual 
patients. 
 
ABCB1 genotype in relation to drug absorption and disposition 
Phenotypical consequences of variants in ABC genes have so far been most 
extensively described for ABCB1, and have mainly focused on the 3435C>T and 
2677G>T/A SNPs. These data are summarized in Table 6 and Table 7, respectively. In line 
with their initial observation of lower duodenal expression of ABCB1 in individuals 
homozygous for the T-allele of the 3435C>T SNP, Hoffmeyer et al. found a higher area 
under the concentration-time curve (AUC) and maximum concentration (Cmax) for the 
substrate drug digoxin in 22 individuals with the TT genotype after oral drug 
administration [68]. However, because plasma concentrations of oral digoxin are 
dependent on both absorption and elimination pathways [77], it cannot be concluded that 
the higher drug concentration observed in the TT genotype group was simply due to 
decreased ABCB1 function at the intestinal level. Indeed, possible effects of the 3435C>T 
polymorphism on the pharmacokinetics of substrate drugs remain highly controversial. For 
example, Kurata et al. reported that the AUC of oral digoxin was significantly higher in  
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Table 6. Effect of ABCB1 polymorphism 3435C>T on substrate drug effects 
Drug Population (CC/CT/TT) Parameter Effects Ref 
Anticancer 
drugs 
    
 Diflomotecan
   
    
cancer patients (5/9/7)  AUC, F  no significant differences [147] 
 Docetaxel 
   
   
   
cancer patients (5/16/7) clearance no significant difference [119] 
 Docetaxel 
   
   
  
cancer patients (21 total) clearance no significant difference [215] 
 Docetaxel 
   
    
cancer patients (62 total) survival no significant difference
  
[216] 
 Etoposide 
   
   
children with ALL (35/41/26) clearance significantly lower with T 
allele 
[217] 
Irinotecan 
   
    
cancer patients (16/35/8) AUC, clearance no significant differences [120] 
 Irinotecan 
   
    
cancer patients (7/17/6) AUC, clearance no significant differences [218] 
 Irinotecan  
   
    
cancer patients (49 total) renal clearance no significant difference [118] 
 Tipifarnib 
   
   
  
cancer patients (29 total) AUC  no significant difference [121] 
 Vincristine 
   
   
cancer patients (52 total) AUC, clearance no significant differences
  
[219] 
Antihypertensives/antiarrhythmics    
 Digoxin 
   
    
volunteers (3/4/1) AUC (rifampin 
induction) 
significantly higher with T 
allele 
[68] 
Digoxin 
   
   
    
volunteers (7/0/7)   Cmax significantly higher in TT [68] 
 Digoxin 
   
   
volunteers (5/4/3) AUC (0-4 and 0-24 h) no significant differences
  
[220] 
 Digoxin 
   
     
volunteers (5/4/4) AUC (0-4 hours) significantly lower with T 
allele 
[221] 
 Digoxin 
   
   
    
volunteers (50 total) AUC, Cmax no significant differences [222] 
 Digoxin 
   
     
volunteers (8/8/8) AUC (0-4 hours), Cmax
  
significantly higher in TTc [114] 
 Digoxin 
   
    
    
volunteers (5/5/5)a F significantly higher in TT [101] 
 Digoxin 
   
   
   
volunteers (117 total) AUC, Tmax significantly lower in TT [223] 
 Digoxin 
   
   
volunteers (14/8/10) AUC (0-4 and 0-24 h) significantly higher in TTc
  
[224] 
 Digoxin 
   
   
  
volunteers (7 total) AUC, Cmax no significant differences
  
[225] 
 Digoxin 
   
   
    
volunteers absorption rate significantly lower in TT [226] 
 Talinolol 
   
   
    
volunteers (13/29/13) AUC, F, Cmax no significant differences [206] 
Immunosuppressants    
 Cyclosporine 
   
     
RT recipients (31/52/41) trough levels  no significant differences [227] 
 Cyclosporine 
   
   
  
volunteers (7/6/1) AUC, Cmax no significant differences
b
  
[228] 
 Cyclosporine 
   
   
  
HT recipients (14 total) AUC, Cmax no significant differences
c [115] 
Cyclosporine 
   
   
  
RT recipients (108 total) trough levels no significant differences [229] 
 Cyclosporine 
   
  
RT recipients (98 total) 
  
trough levels  no significant differencesc
  
[230] 
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Drug Population (CC/CT/TT) Parameter Effects Ref 
 Cyclosporine 
   
  
RT recipients (10 total) oral clearance  significantly higher with T 
allele 
[231] 
Cyclosporine 
   
   
  
RT recipients (15/18/17) trough levels no significant differencesc [232] 
 Cyclosporine 
   
    
RT recipients (28/43/35) AUC, Cmax no significant differences
c
  
[233] 
 Cyclosporine 
   
  
LT recipients (44 total)  dose requirement significantly lower in TT
  
[234] 
 Tacrolimus 
   
    
LT recipients (15/22/9)  concentration/ 
dose ratio 
no significant difference [105] 
 Tacrolimus 
   
     
RT recipients (48/70/62) plasma 
concentrations 
no significant differences [235] 
Tacrolimus 
   
   
  
LT recipients (4/10/3)  neurotoxicity no significant difference [236] 
 Tacrolimus 
   
   
  
HT recipients concentration/dose 
ratio 
no significant difference [237] 
 Tacrolimus 
   
  
RT recipients (62 total) trough concentrations
  
no significant differences
  
[229] 
 Tacrolimus 
   
   
RT recipients (29/34/18) dose requirement no significant differencec
  
[238] 
 Tacrolimus 
   
    
RT recipients (19/24/7) trough levels  no significant differences [232] 
 Tacrolimus 
   
   
  
LT recipients trough levels  no significant differencesc
  
[239] 
 Tacrolimus 
   
   
RT recipients (73 total) trough levels  no significant differencesc
  
[240] 
 Tacrolimus 
   
    
RT recipients (30 total) trough levels  no significant differences [241] 
Miscellaneous     
 Dicloxacillin 
   
   
   
volunteers (17 total) clearance, Cmax no significant differences [242] 
 Fexofenadine
   
    
volunteers (9/16/12) AUC (0-4 hours)
  
significantly lower in TT
  
[76] 
 Fexofenadine
   
     
volunteers (10/0/10) AUC, clearance
  
no significant differences [243] 
 Fexofenadine
   
   
   
volunteers (15/12/6) AUC, Cmax no significant differences
c [116] 
 Loperamide 
   
   
   
volunteers (20 total) AUC, Cmax no significant differences
c [117] 
 Loperamide 
   
   
   
volunteers (8/0/8) AUC, Cmax no significant differences
c [244] 
 Midazolam 
   
    
cancer patients (5/16/7) clearance no significant difference
  
[119] 
 Midazolam 
   
   
   
volunteers (9/5/7) metabolic ratio no significant differencec [112] 
 Nelfinavir 
   
    
HIV-1 patients (10/30/14) plasma 
concentrations 
significantly lower with T 
allele 
[142] 
 Nortriptyline 
   
     
depressed patients (78 total) postural hypotension risk increased in TT  [245] 
 Phenytoin 
   
   
  
volunteers (28/45/23) plasma 
concentrations  
lower in CC  [246] 
Prednisone 
 
   
HT recipients (69 total) steroid dose/weaning more CC remain on 
steroids at 1 year 
[247] 
  Warfarin  AT patients (31/100/70) dose requirement no significant differencec
  
[248] 
Abbreviations: CC, wild-type; CT, heterozygous variant; TT, homozygous variant; AUC, area under the time-concentration 
curve; RT, renal transplant; HT, heart transplant; LT, liver transplant; Cmax, maximum concentration; F, oral bioavailability; 
ALL, acute lymphoblastic leukemia; AT, atrial fibillation. 
a Linked to the polymorphism 2677G>A/T; b AUC and Cmax in the CT and TT genotypes were higher than those in CC group; 
c 
Haplotype analysis performed for the polymorphisms 1236C>T, 2677G>A/T, and 3435C>T. 
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Table 7. Effect of ABCB1 polymorphism 2677G>T/A on substrate drug effects 
Drug Population 
(GG/GT/TT/GA/AA) 
Parameter Effects Ref 
Anticancer drugs 
 Diflomotecan cancer patients (8/8/3/1/0) AUC, F  no significant differences [147] 
 Docetaxel  cancer patients (21) clearance no significant difference [215] 
 Irinotecan  cancer patients  
(12/23/13/4/1)  
AUC, clearance no significant differences [120] 
 Irinotecan  cancer patients  (6/16/6/0/0) AUC, clearance no significant differences [218] 
 Irinotecan  cancer patients (49) renal clearance significantly lower in TTa [118] 
 Tipifarnib cancer patients (29) AUC no significant difference [121] 
Antihypertensives/antiarrhythmics 
 Digoxin  volunteers (50) AUC, Cmax  no significant differences [222] 
 Digoxin volunteers (15) F significantly higher in TT [101] 
 Digoxin  volunteers (117) AUC, Tmax significantly lower in TT [223] 
 Digoxin  volunteers (12/11/7/1/1)
  
AUC (0-4 and 0-24 
hours) 
no significant differences [224] 
 Talinolol  volunteers (67 total)   AUC, F, Cmax no significant differences [206] 
Immunosuppressants 
 Cyclosporine HT recipients (14 total)
  
AUC, Cmax significantly higher in TT [115] 
 Cyclosporine RT recipients (98 total) trough levels  no significant differences [230] 
 Cyclosporine RT recipients (20/21/9/0/0) trough levels  no significant differences [232] 
 Cyclosporine RT recipients (32/51/15/3/0)
  
AUC, Cmax no significant differences [233] 
 Tacrolimus  LT recipients (69 total)  concentration/dose 
ratio 
no significant correlation [105] 
 Tacrolimus  LT recipients (17 total) neurotoxicity  no significant difference [236] 
 Tacrolimus  HT recipients concentration/dose 
ratio 
no significant difference [237] 
 Tacrolimus  RT recipients (26/38/12/3/0) dose requirement no significant difference [238] 
 Tacrolimus  RT recipients (23/16/8/3/0) trough levels no significant differences [232] 
 Tacrolimus  LT recipients  trough levels  no significant differencesa [239] 
 Tacrolimus  RT recipients (73 total) trough levels no significant differencesa [240] 
 Tacrolimus  RT recipients (30 total) trough levels  no significant differences [241] 
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Drug Population 
(GG/GT/TT/GA/AA) 
Parameter Effects Ref 
Miscellaneous     
 Fexofenadine volunteers (60 total) AUC (0-4 hours) significantly lower in TT [76] 
 Fexofenadine volunteers (33 total) AUC, Cmax no significant differences
a [116] 
 Loperamide  volunteers (20 total) AUC, Cmax  no significant differences [117] 
 Loperamide volunteers (16 total) AUC, Cmax no significant differences [244] 
 Midazolam  volunteers (10/7/4/0/0) metabolic ratio no significant difference [112] 
 Prednisone  HT recipients (69 total) steroid 
dose/weaning 
more CC remain on steroids 
at 1 year 
[247] 
 Warfarin  AF patients (57/91/40/9/1) dose requirement no significant difference [248] 
Abbreviations: GG, wild-type; GT/GA, heterozygous variant; TT/AA, homozygous variant; AUC, area under the time-
concentration curve; RT, renal transplant; HT, heart transplant; LT, liver transplant; Cmax, maximum concentration; F, oral 
bioavailability; AT, atrial fibrillation. 
a When analyzed as haplotype for the polymorphisms 1236C>T, 2677G>A/T, and 3435C>T. 
 
subjects with the TT genotype, but there was no difference in AUC after intravenous 
administration of digoxin [101]. 
To explain the observed inconsistencies between the various substrate drugs tested 
(as shown in Tables 6 and 7), a number of potentially confounding factors can be put 
forward. Numerous environmental factors affecting the phenotypical activity of ABCB1 
must be considered, which may include exogenous chemicals, food constituents, herbal 
preparations, and/or therapeutic drug use that may induce or inhibit the function or 
expression of the protein (e.g., rifampin [102] and St. John’s wort [103]). This is 
particularly problematic for cancer patients, who are known to take a wide variety of 
medications concomitantly with their chemotherapeutic regimen [104]. Also, the 
physiological status of the patient may alter ABCB1 function [71]; Goto et al. have 
reported that the 3435C>T polymorphism was associated with neither the expression level 
of ABCB1 mRNA nor systemic concentrations of the immunosuppressive drug tacrolimus 
during the first seven postoperative days in liver transplant recipients [105]. It is likely that 
the expression and phenotypical activity of ABCB1 in these recipients is strongly 
influenced by other medications taken prior to the transplantation and/or by the function 
of the transplanted organ. Thus, these non-genetic factors might mask the potential genetic 
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effects. Therefore, though studies of this type with a heavily pretreated patient population 
may be of limited value in determining the absolute effects of transporter polymorphisms, 
they do provide an indication of the clinical relevance.  
Another explanation for the discrepancies is related to route of drug administration 
and drug-specific differences in metabolism and excretion for various substrates of ABCB1 
[106,107]. For example, cyclosporine is a substrate of the cytochrome P450 3A4 
(CYP3A4) isoform and is transported by ABCB1, whereas digoxin is also a substrate of 
ABCB1 but is not metabolized by CYP3A4. In the case of cyclosporine, reduced ABCB1 
function by possible genetic effects might be compensated for by (inducible) CYP3A4 
activity. Despite the inconsistent results, the significant geographic, ethnic and racial 
differences in the allele  frequency distribution of several ABC transporter genes, including 
the ABCB1 3435C>T variant, interethnic variabilities could also have an impact on drug 
disposition profiles and thus may provide a mechanistic basis for some of the observed 
discrepancies among different populations [73,76,108-111]. Finally, as mentioned earlier, 
distribution of other (unidentified) variation in the same gene and/or other genes relevant 
to drug disposition that may be linked to the 3435C>T polymorphism might be different 
among the different human populations studied. In this context, it is noteworthy that a 
reduced expression of intestinal CYP3A4 mRNA was observed in subjects carrying the TT 
genotype of the 3435C>T polymorphism in a Japanese population [105], although this 
finding could not be confirmed by others [112]. It has also been suggested that the 
interindividual variation of protein expression levels in the human intestine might be 
associated with SNPs in the 5’-regulatory region of the ABCB1 gene (i.e., at nucleotides -
692T>C and -2352G>A) that are possibly in linkage with the 3435C>T polymorphism 
[113]. 
Altogether, the seemingly contradictory findings may indicate that genetic variation 
of ABCB1 3435C>T is not the causal modulator of any of the observed functional 
differences. In addition, the 3435C>T SNP is a silent mutation that does not result in an 
amino acid change. Therefore, it is very likely that this SNP is in linkage disequilibrium 
with other (unidentified) functional polymorphism(s), including the ABCB1 2677G>T/A 
polymorphism. This suggests that functional effects of genetic variants in the ABCB1 gene 
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should be considered as haplotypes rather than independent SNPs. For example, Kim et 
al. demonstrated close linkage of the polymorphisms 1236C>T, 2677G>T, and  3435C>T, 
which makes a variant allele referred to by the investigators as ABCB1*2, whereas an 
allele with the original published sequence is referred to as ABCB1*1 [76]. According to 
their pharmacogenetic study, individuals who are homozygous for ABCB1*1 allele had 
approximately a 40% higher AUC value of fexofenadine, a probe of the ABCB1 activity, 
compared to those who are homozygous for ABCB1*2. Recent work also indicates that the 
use of ABCB1 haplotypes is superior to unphased SNP analysis to predict the 
pharmacokinetics of digoxin [114], cyclosporine [115], and fexofenadine [116], whereas 
Goto et al. suggested a correlation between the haplotype of these three SNPs and 
intestinal expression of ABCB1 mRNA [105]. Assessing haplotypes in the ABCB1 gene and 
consideration of their interethnic differences in future investigations will likely provide 
greater power to detect associations with functional differences [73,111,115,117,118]. 
Although no standard nomenclature for the ABCB1 SNPs and haplotypes is 
currently available, a comprehensive sequence diversity analysis has recently found 33 
haplotypes in at least three chromosomes in a collection of 247 ethnically diverse DNA 
samples [73]. These authors noted two very common haplotypes in the ABCB1 gene, 
referred to as ABCB1*1 for the reference allele and ABCB1*13, which contains three 
common codon polymorphisms (i.e., 1236C>T, 2677G>T, and 3435C>T) as well as three 
intronic variants (10.1, 13.1, and 14.2; see Table 2) [73]. In line with data presented by 
Kimchi-Sarfaty et al. [74], no functional difference was found in the transport of ABCB1 
probe drugs in cells transfected with the ABCB1*1 or ABCB1*13 constructs, either in the 
presence or absence of the ABCB1 inhibitor, GF120918 [73]. As far as anticancer drugs 
are concerned, studies investigating clinical consequences of the ABCB1 polymorphisms 
in terms of their ability to modulate the pharmacokinetic profile of substrates in adults are 
very scarce (Tables 5 and 6). Goh et al. examined the 3435C>T polymorphism in 28 Asian 
patients with cancer who were treated with docetaxel [119]. The genotyping results 
showed no statistically significant difference in docetaxel clearance among the three 
genotypes. Another study explored the relationships in 59 Caucasian patients between 
irinotecan disposition and multiple SNPs in several ABC transporter genes, including the 
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ABCB1 3435C>T polymorphism [120], and no statistical associations were observed. 
Likewise, the ABCB1 3435C>T or 2677G>T/A genotypes did not predict the systemic 
exposure to the farnesyltransferase inhibitor tipifarnib (R115777; Zarnestra) administered 
orally [121]. It should be noted that the lack of relationships between some of the known 
ABCB1 polymorphisms and the pharmacokinetics of these agents is consistent with 
preclinical observations in Abcb1-deficient mice as well as clinical data that metabolism 
rather than transport is the prominent elimination pathway for docetaxel [122,123], 
irinotecan [124,125], and tipifarnib [126]. 
 
ABCB1 genotype in relation to disease risk 
In contrast to the negative data obtained with studies evaluating ABCB1 genotype 
in relation to substrate drug pharmacokinetics, recent studies suggest that common allelic 
variants in the ABCB1 gene may influence the susceptibility to specific diseases and 
therapy outcome (recently reviewed by Marzolini et al. [15] and Jamroziak and Robak 
[127]). These include associations between the ABCB1 3435C>T polymorphism and 
survival of patients with acute myeloid leukemia [128] or acute lymphoblastic 
leukemia[129], response to preoperative chemotherapy for breast cancer [130], the risk 
for developing non-clear cell renal-cell carcinoma [131], response to antiepileptic 
treatment [132], susceptibility to ulcerative colitis [133-137] or Parkinson’s disease 
[138,139], and the incidence of osteonecrosis of the femoral head [140] or chronic renal 
dysfunction [141]. The ABCB1 3435C>T polymorphism has also been recently found to 
be associated with the CD4 response to treatment of HIV infections [142,143], although in 
subsequent studies this effect was not demonstrated to translate into changes in phase I 
viral decay [144], disease progression before treatment [145], or the response to 
antiretroviral therapy in drug-naive HIV-positive patients [146]. A recent study has also 
found significant associations between ABCB1 haplotypes and both refractory Crohn’s 
disease and ulcerative colitis[136]. Nonetheless, these intriguing findings require 
confirmation in larger patient populations as well as other ethnic groups with known 
differences in allele and genotype frequencies. 
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Figure 2. Schematic structure of ABCG2 and its variants. 
 
ABCG2 genotype in relation to drug absorption and disposition 
In contrast to ABCB1, there have been only few studies reporting links between 
genotype and phenotype for ABCG2 (Table 8). However, those that have been carried out 
exhibit promising and fairly consistent results. The focus of these studies has been 
primarily on the ABCG2 421C>A SNP. Initial experiments evaluated the effects of this 
polymorphism along with the 34G>A SNP, in comparison with wild-type ABCG2 
transfected PA317 cells [85]. The drug concentrations causing 50% inhibition of cell 
growth (IC50) values in in vitro assays were determined for the anticancer substrate drugs 
SN-38, mitoxantrone, and topotecan. ABCG2 was shown to mediate the efflux of all three 
drugs, with significantly higher IC50 values for cells with ABCG2 (transfected) as 
compared to those without ABCG2 (non-transfected). There was no significant difference 
between the G34A mutant and wild-type ABCG2. However, the variant 421A cells 
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demonstrated a significant decrease in IC50 for all three drugs as compared to wild-type, 
reducing, but not eliminating, drug efflux. For example, the IC50 for the irinotecan 
metabolite SN-38 was 2.5, 98, and 30 ng/ml in untransfected PA317 cells, cells 
transfected with wild-type ABCG2, and homozygous transfected C421A mutant cells, 
respectively. Similar experiments were carried out with stably transfected HEK-293 cells in 
which the homozygous 421A variant cells demonstrated a significantly lower 
mitoxantrone efflux and an IC50 value that was 6-fold lower than that for the cells 
transfected with the wild-type protein [94]. 
 
Table 8. Effect of ABCG2 polymorphism 421C>A on anticancer drug effects 
Drug Test system (CC/CA/AA) Parameter Effect Ref 
Diflomotecan cancer patients (15/5/0) AUC (i.v.) significantly higher with A allele [147] 
Irinotecan cancer patients (68/14/2) 
AUC of SN-
38 
no significant difference [87] 
Mitoxantrone PA317 cells (CC vs AA) IC50 significantly decreased in AA [85] 
Mitoxantrone HEK-293 cells (CC vs AA) drug efflux significantly decreased in AA [94] 
Mitoxantrone LLC-PK1 cells (CC vs AA) IC50 significantly decreased in AA [89] 
SN-38 PA317 cells (CC vs AA) IC50 significantly decreased in AA [85] 
Topotecan cancer patients (10/2/0) AUC (oral), F significantly higher with A allele [91] 
Topotecan PA317 cells (CC vs AA) IC50 significantly decreased in AA [85] 
Topotecan LLC-PK1 cells (CC vs AA) IC50 significantly decreased in AA [89] 
Abbreviations: CC, wild-type; CA, heterozygous variant; AA, homozygous variant; AUC, area under the time-
concentration curve; i.v., intravenous; IC50, drug concentration causing 50% inhibition of cell growth; F, oral 
bioavailability. 
 
The first study linking the ABCG2 421C>A polymorphism with altered drug 
exposure in vivo has recently been completed. Diflomotecan, a topoisomerase I inhibitor 
and substrate for ABCG2, was administered to 22 patients both intravenously and orally 
[147]. After intravenous administration, the AUC in patients heterozygous for the variant 
allele (5 individuals) showed an area under the curve (AUC) that was 299% of that for 
those patients homozygous for the wild-type allele. After oral dosing, the bioavailability 
was significantly lower in the heterozygous variant group as compared to the homozygous 
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mutant (31.5% compared to 73.7%), suggesting a more prominent role for ABCG2 in 
elimination than absorption for this particular agent. Indeed, the direct effect of ABCG2 
genotype on the pharmacokinetics of diflomotecan after oral administration was much less  
pronounced that that seen after intravenous administration. This suggests that there may 
be other factors affecting intestinal transport of this drug. However, this study provides a 
starting point for further, larger-scale studies on the effect of this polymorphism on the 
pharmacokinetics of diflomotecan and other ABCG2 substrates. 
A pilot study of the ABCG2 421C>A polymorphism in cancer patients undergoing 
treatment with the structurally-related agent topotecan, a combined substrate for ABCB1 
and ABCG2, produced similar results [91]. The heterozygous CA allele was associated 
with a 1.34-fold increased oral bioavailability of topotecan (31.4% (wild-type) versus 
42.0% (heterozygous); P = 0.037). Interestingly, the lowest combined mRNA expression 
levels of ABCG2 and ABCB1 in small intestinal biopsies was observed in one of the 
patients that was heterozygous variant for ABCG2 421C>A [91].  
In contrast to the observations with diflomotecan and topotecan described above, 
circulating concentrations of the ABCG2 substrates SN-38 and SN-38-glucuronide (SN-
38G) following the administration of irinotecan to 84 Caucasian cancer patients were not 
statistically significantly dependent on ABCG2 421C>A genotype [87]. The frequency of 
the variant allele in this retrospective study was 10.7%, with 14 heterozygotes and 2 
homozygous variants within the group. Overall, the results from this investigation suggest 
that other processes involved in irinotecan metabolism and elimination that exhibit great 
interindividual variation might be over-shadowing any effect of this ABCG2 
polymorphism. It is noteworthy, however, that one of the two patients homozygous for 
ABCG2 421C>A exhibited very extensive accumulation of SN-38 and SN-38G, developed 
very severe side effects including grade 4 leukocytopenia, neutropenia, and diarrhea, and 
died within 9 days after drug administration. Hence, it cannot be ruled out that patients 
with the rare genotype of two variant alleles for ABCG2 421C>A may have severely 
impaired ability to eliminate SN-38 or other ABCG2 substrate drugs. 
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Expert opinion 
The ABC transporters ABCB1 (P-glycoprotein) and ABCG2 (BCRP, MXR, ABCP) 
have an established role in the pharmacokinetic behavior of many substrate drugs, 
including anticancer agents, as well as in the occurrence of multidrug resistance in 
malignant cells. Several polymorphic variants of ABC genes have been described recently, 
of which some, including those of the ABCB1 and ABCG2 genes, may alter protein 
expression and/or function in humans. The effects of genetic variants in ABC transporter 
genes in relation to its phenotypical consequences are still debatable, as contradictory and 
unexplainable results have been reported, especially for the common naturally-occurring 
ABCB1 3435C>T variant. Most studies published to date clearly suffer from small sample 
sizes evaluated in relation to the often low allele frequency of the studied variant, as well 
as from a host of other potentially confounding factors that are likely to influence their 
outcome. Most important among these are environmental and physiological factors that 
may affect expression of the transporters, and links to other (unknown) genes or variants of 
putative relevance for drug absorption and disposition pathways. The use of haplotype 
profiles as opposed to testing unphased SNPs to predict certain phenotypes has been 
proposed [73], and it cannot be excluded that this may have clinical importance, but this 
remains to be clarified for most drugs. In addition, more detailed investigations into the 
influence of ethnicity on ABC transporter function and expression is urgently needed. 
Nevertheless, in view of the substantial degree of inter-individual variability in systemic 
exposure to most anticancer drugs (up to 40-fold; [148]), it can be predicted that 
variability in ABC transporter expression as a result of a certain genotype (up to 2-fold; 
[68,86]) is presumably relatively unimportant. This hypothesis is consistent with literature 
findings indicating that ABCB1 and ABCG2 genotype has little, if any, effect on the 
pharmacokinetics of substrate drugs unless transport is the crucial process in the agent’s 
oral absorption or disposition pathways (e.g., as in the case of ABCG2 421C>A in relation 
to the pharmacokinetics of diflomotecan [147] and topotecan [91]). In the field of drug 
resistance, the pharmacogenetic aspects of ABC transporters are unfortunately still largely 
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unexplored, but this may eventually contribute to individualizing treatment of patients 
with cancer on the basis of tumor genotyping. 
 
Outlook 
Substantial progress has been made in recent years toward an understanding of the 
functional significance of polymorphic ABC transporter proteins, although various aspects 
in this area require more work before it becomes more useful clinically as a prospective 
tool to predict treatment outcome. Over the next decade, the importance of ABC 
transporter pharmacogenetics with classical anticancer drugs will be defined; however, it 
will also be of importance for the rational development of new agents designed to exploit 
advances in molecular oncology and those acting on oncogenes, tumor suppressor genes 
and related signal transduction pathways, including apoptosis, as well as agents used to 
inhibit invasion, angiogenesis, and metastasis. The ongoing development of improved 
genomic methods, for example those based on DNA chip technology, will also be a major 
factor in the growing influence of ABC transporter pharmacogenetics as a factor 
contributing to anticancer drug pharmacology. Similar to the discoveries of functional 
genetic variations in drug efflux transporters of the ABC family, SNPs will be identified in 
transporters that facilitate cellular uptake of anticancer drugs, and this will likely have a 
profound impact on attempts to further optimize cancer chemotherapeutic treatment. 
 
Highlights 
• ATP-binding cassette (ABC) genes play a significant role in the resistance of malignant 
cells to a variety of anticancer agents, including taxanes, anthracyclines, 
epipodophyllotoxins, and Vinca alkaloids. 
• The ABC gene products, including ABCB1 (P-glycoprotein) and ABCG2 (BCRP, MXR, 
ABCP) are also known to influence oral absorption and disposition of a wide variety of 
drugs. 
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• The expression levels of the ABC transporter proteins in humans have important 
consequences for an individual’s susceptibility to certain drug-induced side effects, 
interactions, and anticancer treatment efficacy. 
• Naturally occurring variants in the ABCB1 and ABCG2 genes have been identified that 
might affect the function and expression of the encoded protein. 
• The frequency of many variant alleles in the ABCB1 and ABCG2 genes are 
significantly ethnically/racially dependent. 
• Whereas the functional significance of variants in ABCB1 is inconclusive and 
controversial, there is increasing evidence that certain single-nucleotide polymorphisms 
(SNPs) in ABCG2 are promising as a predictor of exposure to anticancer substrate drugs. 
• The usefulness of haplotypes as opposed to testing unphased SNPs to predict certain 
phenotypes has been documented. 
• Additional clinical studies are needed to evaluate the clinical usefulness of ABC 
transporter genotyping as a prospective tool to predict the outcome of anticancer 
treatment. 
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Abstract 
A liquid chromatographic assay with mass-spectrometric detection was developed 
for the quantitative determination of the cytochrome P450 3A phenotyping probe 
midazolam in human plasma. Sample pretreatment involved a one-step extraction of 600 
µl aliquots with ethyl acetate. Midazolam and the internal standard, lorazepam, were 
separated on a column (150 × 4.6 mm, I.D.) packed with 5-µm Zorbax Eclipse XDB-C8 
material, using a mobile phase composed of methanol and 10 mM aqueous ammonium 
acetate (60:40, vol/vol). Column eluants were analyzed using mass-spectrometry with an 
atmospheric pressure chemical ionization interface. Calibration curves were linear in the 
concentration range of 1.00 to 200 ng/ml. The accuracy and precision ranged from 92.8% 
to 112% and from 0.056% to 13.4%, respectively, for 4 different concentrations of quality 
control samples analyzed in triplicate on 8 separate occasions. The developed method was 
subsequently applied to study the pharmacokinetics of midazolam in a group of 35 human 
subjects at a single dose of 25 µg/kg. 
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Introduction 
Midazolam is an imidiazobenzodiazepine that is used clinically for sedative 
purposes prior to minor medical procedures and surgery [1]. Midazolam is almost 
completely metabolized to 1’-hydroxy-midazolam and, to a lesser extent, to 4’-hydroxy-
midazolam via two enzymes in the cytochrome P450 (CYP) CYP3A subfamiliy, CYP3A4 
and CYP3A5 [2]. Currently, medications are dosed based upon the assumption that the 
general population metabolizes drugs at approximately the same rate. However, it has 
been shown that hepatic CYP3A microsomal activity may vary as much as 40 fold in vitro, 
and 5-fold differences have been observed in vivo [3]. Such a wide range of metabolic 
activity present in the population may lead to unwanted therapeutic outcomes such as sub-
therapeutic or toxic drug levels. Due to this wide variability in CYP3A expression, the need 
for the use of an in vivo probe such as midazolam to predict the CYP3A metabolic 
phenotype of patients treated with narrow therapeutic window agents is evident [3,4]. For 
the purpose of CYP3A phenotyping, doses of midazolam administered to humans are 
typically very low, which poses a significant challenge on analytical methods. In contrast 
to gas chromatographic methods with electron capture or mass spectrometric detection [5-
9], most of the currently available validated liquid chromatographic methods used to 
determine midazolam in human plasma are hampered by a lack in sensitivity to allow for 
accurate estimation of complete pharmacokinetic profiles, necessitate the use of large 
sample volumes for extraction (≥ 1 mL) [10,11], and/or require triple-quadrupole mass 
spectrometry [12], which is not available in most laboratories (Table 1). Here, we describe 
a novel, sensitive analytical method for the determination of midazolam concentrations in 
human plasma based on liquid chromatography coupled with single-quadrupole mass-
spectrometric detection. 
Experimental 
Chemicals 
Midazolam (lot # 081-122-1; purity, 99.5%) was obtained from UFC Ltd. 
(Manchester, United Kingdom). The internal standard lorazepam originated from Sigma (St.  
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Louis, MO, USA). All other chemicals and solvents were of analytical grade or better. 
Deionized water was generated with a Hydro-Reverse Osmosis system (Durham, NC, USA) 
connected to a Milli-Q UV Plus purifying system (Malbourough, MA, USA). Drug-free 
heparinized human plasma was obtained from the National Institutes of Health Clinical 
Center Blood Bank (Bethesda, MD, USA). 
 
Preparation of Stock Solutions and Standards 
Stock solutions of midazolam were prepared independently in triplicate by 
dissolving the appropriate amount of drug, corrected for impurity, in HPLC-grade methanol 
at a concentration of 0.500 mg/ml, and were then stored in glass at –20ºC for up to 4 
weeks. The difference in drug concentration in each of the triplicate stock solutions, 
estimated from the mean peak area following repeat analysis of a dilution of the stock, was 
determined to be within 5%. Out of one of the midazolam stock solutions, a working 
solution containing 100 µg/ml was prepared in methanol, which was further used for the 
construction of calibration samples and quality control (QC) samples. An internal standard 
working solution of 4 µg/ml was prepared by dilution with HPLC-grade methanol, and was 
stored for later use at –20ºC. 
 
Sample pretreatment 
Samples were prepared by spiking 600 µl blank human plasma in 15 ml 
polypropylene tubes with midazolam at the indicated concentrations (below), and 
lorazepam at a final concentration of 100 ng/ml (25 µl of the methanolic working 
solution). Blank samples and samples containing only internal standard were corrected for 
methanol content, so all samples had a final methanol content of 7.7% . After adding 600 
µl of 0.1 M ammonium acetate, the samples were vortex-mixed and 4 ml of water 
saturated ethyl acetate was added to each tube. The samples were vortex mixed for 1 min 
and then centrifuged at 2000 g for 5 min (4˚C). The organic phase was transferred to a 
clean glass tube using a disposable plastic pipette, and evaporated to dryness under a 
continuous stream of air at 40˚C. The extracts were reconstituted with 125 µl of a mixture 
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of methanol and 0.01 M ammonium acetate (60:40, vol/vol), and 75-µl was injected for 
chromatographic analysis. 
 
Equipment 
Chromatography was performed on a HP1100 system (Agilent Technology, Palo 
Alto, CA, USA), which included a binary pump, a refrigerated autosampler, a degasser, a 
photodiode-array detector, and a single-quadrupole mass-spectrometric (MS) detector 
(Agilent 1100 MSD) equipped with an atmospheric pressure chemical ionization source. 
The autosampler was maintained at 4 °C and the column was at ambient temperature. The 
analytes were separated on a stainless steel column (150 × 4.6 mm I.D.) packed with 5-µm 
particle size Zorbax Eclipse XDB-C8 material (Agilent), preceeded by a Zorbax phenyl (4.6 
× 12.5 mm I.D., 5 µm particle size) guard colum (Agilent). Samples were eluted 
isocratically using a mobile phase composed of methanol – 0.01 M ammonium acetate 
(60:40, vol/vol) at a flow rate of 1.0 ml/min. The MS conditions were as follows: 
fragmentor, 90 V; gain, 1; drying gas flow, 5 liter/min; nebulizing gas pressure, 55 psi; 
drying gas temperature, 330˚C; and capillary voltage, 2200 V. Selected-ion monitoring was 
accomplished at m/z 326 for midazolam, and m/z 322 for the internal standard. 
The chromatographic data were collected and analyzed using the software package 
Chemstation (Agilent). Calibration graphs were calculated by least-squares linear 
regression analysis of the peak area ratio of midazolam and the internal standard versus the 
drug concentration of the nominal standard. The zero concentration sample (blank) was 
used to visually verify the purity of the reagents and the lack of other potentially interfering 
(endogenous) substances, but was not considered for the regression analysis of standards. 
The goodness-of-fit of various calibration models was evaluated by visual inspection, the 
correlation coefficient and an ANOVA lack-of-fit test. 
 
Validation procedures 
Method validation with respect to accuracy and precision was performed according 
to procedures described in detail elsewhere [13]. Calibration standards in drug-free human 
heparinized plasma were prepared freshly by serial dilution at midazolam concentrations 
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of 1.00, 2.00, 5.00, 10.0, 30.0, 100, and 200 ng/ml, such that the total amount of 
methanol added was identical in each sample. Pools of quality-control (QC) samples of 
midazolam in plasma were prepared similarly at concentrations of 1.00, 3.00, 85.0, and 
170 ng/ml, and stored in batch at –20ºC for the duration of the validation procedure. 
Validation runs included a calibration curve and QC samples analyzed in triplicate and 
were performed on 8 separate occasions. The lower limit of quantitation (LLOQ) of the 
assay was assessed by determining the concentration of midazolam at which the values for 
precision and accuracy were less than 20%, excluding outliers.  
The accuracy and precision of the assay were assessed by the mean relative 
percentage deviation (DEV) from the nominal concentrations and the within-run and 
between-run precision, respectively.  The accuracy for each tested concentration was 
calculated as: 
DEV = 100 × {([analyte]mean – [analyte]nominal)/[analyte]nominal} 
Estimates of the between-run precision were obtained by one-way analysis of 
variance (ANOVA) using the run day as the classification variable.  The between-groups 
mean square (MSbet), the within-groups mean square (MSwit), and the grand mean (GM) of 
the observed concentrations across runs were calculated using the software package NCSS 
2001 (J. Hintze, Number Cruncher Statistical Systems, Kaysville, UT, USA).  The between-
run precision (BRP), expressed as a percentage relative standard deviation, was defined as: 
! 
BRP =100 " ( ((MSbet #MSwit) /n) /GM)  
where n represents the number of replicate observations within each run.  For each 
concentration, the estimate of the within-run precision (WRP) was calculated as: 
)/)((100 GMMSWRP wit!=  
The extraction efficiency of the assay, expressed as a percentage, was measured by 
comparison of extracted plasma samples and aqueous samples injected without extraction 
in replicates of five at midazolam concentrations of 1.00, 3.00, 85.0, and 170 ng/ml.   
Possible matrix effects were investigated by infusing a 15 µM solution of midazolam 
into the MS, post column using a syringe pump via a tee. After a constant response was 
established, five blank plasma samples that had been extracted and reconstituted, as 
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detailed above, were injected. A slight matrix effect was noted at a retention time of 2 
minutes. No further matrix effects were noted, showing that there is no interference with 
midazolam and lorezepam, both of which have significantly longer retention times. 
 
Pharmacokinetic analysis 
Midazolam (Roche Laboratories, Nutley, NJ, USA) was injected intravenously over a 
30 to 60-second period at a dose of 25 µg/kg to 35 human subjects. Blood samples (7-ml 
each) were collected prior to drug administration, and at 5 and 30 min, and 1, 2, 4, 5, and 
6 hours post-infusion. The samples were centrifuged at 2000 g for 10 min (4 °C) 
immediately after collection, and were stored at –20 °C at the day of collection and at –80 
°C afterwards, until the day of analysis. The current experiment was approved by the 
Institutional Review Board, and the patients signed informed consent before study entry for 
the blood sampling procedure. Plasma concentration-time data of midazolam were 
analyzed by a non-compartmental model using the software package WinNonlin v4.0 
(Pharsight Corporation, Mountain View, CA, USA). 
 
Results and discussion 
Specificity 
Figure 1 displays typical chromatograms of an extract of a blank human plasma 
sample (A), an extract of a plasma sample spiked with midazolam at a concentration of 1 
ng/ml (B), and an extract of a plasma sample taken at 5 hours after the administration of 
midazolam (dose, 25 µg/kg) (C). The chromatographic peaks showed symmetrical resolution, 
with no interfering peaks present for all compounds in drug-free specimens, obtained from 6 
individuals. Midazolam (tR =  11.36 min) and the internal standard lorazepam (tR = 6.79 
min) were well separated, and the overall chromatographic run time was established at 15 
minutes. The selectivity and resolution of the chromatographic system was also confirmed 
by co-injection of midazolam with one of its major metabolites, 1’-hydroxy-midazolam. 
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Fig. 1. Chromatograms from reversed-phase HPLC analysis of a blank human plasma sample (A), a 
human plasma sample spiked with midazolam at a concentration of 1 ng/ml (B), and a plasma 
sample obtained from a female patient with cancer at 5 hours after intravenous administration of 
midazolam (dose, 25 µg/kg) (C). The labeled chromatographic peaks indicate midazolam (II) and 
the internal standard lorazepam (I).  
 
 
Validation characteristics 
The measurement variance over the range of 1.00 to 200 ng/ml increased 
proportionally with the midazolam concentration, as detected by a one-sided F-test at an 
α-value of 5%. Therefore, a weighting factor was applied inversely proportional to the 
variance at the given concentration level (1/[nominal midazolam concentration]2). Using 
least-squares linear-regression, a mean (± standard deviation) correlation coefficient of 
0.9974 ± 0.00176 (range, 0.9946 to 0.9988) was obtained (Table 2). The statistical 
evaluation of the coefficients of the mean ordinary least-squares line indicated an 
acceptable degree of bias in the slope (coefficient of variation, 8.20%) and in the intercept 
(coefficient of variation, 40.7%), suggesting minor matrix and blank effects [14]. In blank 
human plasma spiked with midazolam at a concentration of 1.00 ng/ml, only 2 out of 24 
samples were outside the acceptable ± 20% deviation limits for accuracy [13], while the 
remaining samples had a mean percentage deviation from the nominal concentration and 
within and between-run variability of ±7.23%, 0.056%, and 13.4%, respectively. Based on  
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Table 2. Back-calculated concentrations from calibration curves run in duplicate on four 
occasions 
Nominal GMa SD DEV RSD n 
(ng/ml) (ng/ml) (%) (%)   
1 1.05 0.062 5.13 5.89 8 
2 1.93 0.262 -3.68 13.6 6 
5 4.64 0.227 -7.23 4.89 8 
10 10.2 0.247 1.52 2.43 8 
30 31.9 1.43 6.34 4.48 7 
100 101 1.36 1.4 1.34 8 
200 199 5.27 -0.388 2.65 8 
a Abbreviations: GM, grand mean; SD, standard deviation; DEV, percent deviation from nominal 
value; RSD, relative standard deviation; n, total number of replicate observations within the validation 
runs.  
 
these results, the lower limit of quantitation for midazolam was established at 1.00 ng/ml. 
This represents a 7 to 100-fold increase in sensitivity as compared to assays based on 
HPLC with UV detection (Table 1).  
Validation data of the analytical method in terms of accuracy and precision are 
summarized in Table 3. Based upon analysis of QC samples analyzed on 8 different 
occasions, the final method was shown to be accurate, with an average accuracy at the 4 
tested concentrations within 12%, and precise, with a within-run and between-run 
precision always within 15%. The mean overall extraction efficiency for midazolam was 
independent of the spiked concentration, and not significantly different from 100%. 
Table 3. Assessment of accuracy and precision from quality-control samples* 
Nominal GMa SD DEV BRP WRP n 
(ng/ml) (ng/ml) (%) (%) (%)   
1 0.928 0.476 -7.23 13.4 0.056 22 
3 3.13 0.312 4.48 12.1 0.112 22 
85 94.9 8.42 11.6 2.58 0.865 24 
170 160 8.89 -5.6 4 0.608 24 
a Abbreviations: GM, grand mean; SD, standard deviation; DEV, percent deviation 
from nominal value; WRP, within-run precision; BRP, between-run precision; n, total 
number of replicate observations during the validation runs. * Three samples at each 
concentration were run on 8 different occasions. 
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Plasma concentration-time profile 
The mean observed concentration-time profile of midazolam in a group of 35 
human subjects (median dose, 1.8 mg; range, 1.2 – 2.7 mg) is shown in Figure 2. The 
mean (± standard deviation) observed peak concentration of midazolam in this group was 
62.8 ± 22.0 ng/ml, with a mean area under curve extrapolated to infinity of 96.1 ± 42.7 
ng·h/ml and a mean systemic clearance of 360 ± 132 ml/min (range, 118 – 704 ml/min), 
which is similar to previously obtained values [2]. In 28 of 35 subjects, the observed 
midazolam concentration had already dropped below 5 ng/ml at 4 hours after drug 
administration (overall mean concentration, 4.46 ± 2.50 ng/ml). This provides further 
evidence that for the purpose of CYP3A phenotyping with non-sedative doses of 
midazolam, an analytical method is required with a lower limit of quantitation at the low 
ng/ml level to avoid the generation of overestimated values for drug clearance. 
 
 
Fig. 2. Mean plasma concentration-time profile of midazolam following intravenous 
administration of midazolam at a dose of 25 µg/kg to a group of 35 human subjects 
(median total dose, 1.8 mg). Symbols represent mean values, and error bars represent 
standard deviations. 
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Conclusion 
In conclusion, we have described a novel method for the quantitative determination 
of midazolam in human plasma, which is specific, accurate and precise, and can be easily 
implemented in routine practice. The sample pretreatment procedure is based on a simple 
and efficient solvent extraction, thereby eliminating the need of solid phase extraction, 
column switching procedures, and/or the use of large volumes of plasma for sample clean-
up. Compared to a previously described assay for the determination of midazolam with 
single-quadrupole mass spectrometric detection [15], this new method provides superior 
sensitivity, at a lower limit of quantitation of 1.00 ng/ml, using only 600-µl sample 
aliquots. The method will be implemented in current and future clinical pharmacokinetic 
investigations in which midazolam is used as a CYP3A phenotyping probe.  
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Abstract 
Purpose: To evaluate the impact of naturally-occurring variants in genes encoding 
the cytochrome P450 isoforms CYP3A4 and CYP3A5 in patients with cancer receiving 
midazolam as a phenotyping probe. 
Experimental Design: Five variants in CYP3A4 and CYP3A5 were evaluated in 58 
patients (21 women and 37 men) receiving a short i.v. bolus of midazolam (dose, 0.0145 
or 0.025 mg/kg). Midazolam concentrations in plasma were determined using liquid 
chromatography-mass spectrometry, and pharmacokinetic parameters were calculated 
using non-compartmental analysis. Genomic DNA was characterized for the variants by 
PCR-restriction fragment length polymorphism, and all genotypes were confirmed by 
direct nucleotide sequencing. 
Results: The mean clearance of midazolam was 24.4 ± 9.12 L/h, and phenotypic 
CYP3A activity varied about 4-fold in this population (range, 10.8 to 44.3 L/h). There were 
six carriers of the CYP3A4*1B allele (allele frequency, 0.061). No variant alleles for 
CYP3A4*17, CYP3A4*18A, or CYP3A5*6 were identified. Forty-eight of the 58 patients 
were homozygous variant for CYP3A5*3C, eight were heterozygous, and two were 
homozygous wild-type (allele frequency, 0.897). No associations were noted between any 
of the studied genotypes and the phenotypic measures (P ≥ 0.16). Likewise, a common 
variant in exon 26 in the gene encoding P-glycoprotein (i.e., ABCB1 (MDR1) 3435C>T) 
that was previously reported to be linked to CYP3A4 mRNA levels was unrelated to any of 
the studied phenotypic measures (P ≥ 0.49). 
Conclusions:  The studied genetic variants in CYP3A4 and CYP3A5 are unlikely to 
have an important functional significance to phenotypic CYP3A activity in patients with 
cancer. 
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Introduction 
Isoforms of the cytochrome P-450 (CYP) 3A subfamily are the most abundantly 
expressed CYP enzymes in the human liver [1].  In adults, CYP3A4 and CYP3A5 are 
predominant among the four known isoforms (CYP3A4, CYP3A5, CYP3A7, and CYP3A43) 
in the liver and intestines [1]. However, metabolically active CYP3A5 is expressed only by 
an estimated 10 to 30% of Caucasians and 50 to 60% of African Americans [2,3]. The 
genetic basis for polymorphically expressed CYP3A5 was recently reported to be 
associated with a single nucleotide polymorphism (SNP) in intron 3 of the CYP3A5 gene 
(CYP3A5*3C) [4,5]. This SNP causes alternative splicing and truncation of CYP3A5 
protein, and provides the basis for the absence of CYP3A5 protein in most individuals of 
Caucasian descent.  In people with at least one CYP3A5*1A wild-type allele, CYP3A5 
accounts for at least 50% of the total CYP3A content, and results in approximately 2- to 3-
fold higher total CYP3A activity in vitro [4,6]. The most prevalent polymorphism in 
CYP3A4 (CYB3A4*1B) occurs in the 5’ flanking region of the gene. The frequency of this 
allele ranges from 2 to 9.6% in Caucasians to 35 to 67% in African Americans [1]. 
Wide variation in CYP3A expression and activity exists in humans, which is 
reflected by extensive interindividual differences in the clearance of CYP3A substrate 
drugs and phenotyping probes like midazolam [7]. For many anticancer drugs used 
therapeutically, pharmacokinetic variability is a significant contributor to the variability of 
both the severity of side effects and therapeutic response [8]. Furthermore, the metabolism 
of 37% of all currently approved cytostatic and/or cytotoxic anticancer agents is known to 
be mediated, at least in part, by the CYP3A isoforms. Hence, identification of factors 
affecting the clearance of CYP3A substrates could aid in predicting or adapting 
appropriate, individualized doses of anticancer drugs. Here, we evaluated the impact of 
common naturally-occurring variants in genes encoding CYP3A4 and CYP3A5 in cancer 
patients receiving midazolam as a phenotyping probe. 
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Methods 
Patient Selection 
This study was conducted under two Institutional Review Board approved 
protocols and all patients signed an informed consent form prior to treatment. Patients 
with a histologically or cytologically confirmed diagnosis of malignant solid tumor were 
eligible for two clinical trials in which patients underwent CYP3A phenotyping with 
intravenously administered midazolam [9,10]. Eligibility criteria included: age >18 years; 
performance status ≤ 1; adequate hematopoietic (leukocytes, ≥ 4.0× 109/L; neutrophils, ≥ 
1.5× 109/L; and platelets, ≥ 100× 109/L), hepatic (bilirubin within normal limits; 
transaminases, ≤ 2 times the upper limit of normal) and renal function (creatinine 
clearance, ≥ 50 mL/min). All patients were required to have an estimated life expectancy 
of more than 12 weeks, and no previous chemotherapy was allowed for at least 4 weeks 
prior to enrollment. The patients were asked to abstain from substances known to affect 
the function and/or expression of CYP3A and/or ABCB1 for a period of 2 weeks before, 
during, and up to 3 weeks after the administration of midazolam. 
 
Blood Sampling and Processing 
 Blood samples were collected in glass tubes containing heparin. Samples were 
drawn at 5, and 30 minutes and 1, 2, 3, 4, and 5 hours following bolus i.v. administration 
of midazolam at a dose of either 0.0145 or 0.025 mg/kg. In about half of the patients, 
additional samples were obtained at 15 minutes and 6 hours after midazolam 
administration. Immediately after collection, each sample was centrifuged for 10 minutes 
at 2000 g (4 °C), and plasma supernatants were stored at –80 °C until the day of analysis. 
 
Drug Measurement and Pharmacokinetic Analysis 
Quantitation of midazolam in plasma was performed by high-performance liquid 
chromatography with mass spectrometric detection, as described previously [11]. 
Pharmacokinetic profiles of midazolam were analyzed by non-compartmental methods 
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using the software package WinNonlin version 4.0 (Pharsight, Mountain View, CA). The 
parameters calculated included area under the plasma concentration-time curve 
extrapolated to infinity (AUC), clearance (CL; calculated as dose/AUC), volume of 
distribution at steady-state (Vss), and half-life of the terminal phase (t1/2,z). The AUC was 
normalized to a dose of 0.025 mg/kg. As a comparison, the AUC was also calculated 
based on the limited sampling model described previously [12].  
 
CYP3A4 and CYP3A5 Genotype Analysis 
Plasma was used to isolate genomic DNA according to the manufacturer’s 
instructions using the UltraSens Virus Kit (Qiagen, Valencia, CA). Variations in CYP3A4 
(CYP3A4*1B, CYP3A4*17, CYP3A4*18A) and CYP3A5 (CYP3A5*3C, and CYP3A5*6) were 
analyzed using restriction fragment length polymorphism (RFLP) based techniques, as 
previously described [13,14]. Confirmation of all the variant genotype assignments (i.e., 
for CYP3A4*1B, CYP3A5*3C, and CYP3A5*6) was done using direct nucleotide 
sequencing. 
In preparation for sequencing, an initial polymerase chain reaction (PCR) was 
performed with concentrated DNA utilizing 20 pmol of each primer.  For CYP3A4*1B, the 
primers were designed and chosen as follows:  5’-CTGTGTGAGGAGTTTGGTGAG-3’ 
(CYP3A4*1B F3), and 5’-TGGAAGAGGCTTCTCCACCTTG-3’ (CYP3A4*1B R3). These 
primers were added to a reaction mixture of 1× PCR buffer (Perkin-Elmer), 2 mM of each 
of the four deoxynucleotide triphosphates (dNTPs), 1.5 mM MgCl2, and 2 units of 
Platinum Taq polymerase (Invitrogen, Carlsbad, CA) in a reaction volume of 20 µL. The 
temperature profile for the PCR reaction was one cycle at 94oC for 5 minutes, followed by 
20 cycles of 94oC for 30 seconds, 62oC for 30 seconds, and 72oC for 30 seconds, with a 
final 7-minute cycle at 72oC. After initial amplification, 3 µL of amplified product was 
removed and an additional PCR amplification was performed using 40 pmol of the 
primers 5’-GCTCTGTCTGTCTGGGTTTGG-3’ (CYP3A4*1B F4) and 5’-
CACACCACTCACTGACCTCCT-3’ (CYP3A4*1B R4) in a 50-µL reaction. PCR conditions 
were 94oC for 5 minutes, followed by 40 cycles of 94oC for 30 seconds, 64oC for 30 
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seconds, and 72oC for 30 seconds, with a final 7-minute cycle at 72oC. Sequencing was 
performed using the following primers: (CYP3A4*1B F5) 5’-
AGGTGTGGCTTGTTGGGATG-3’ for the forward strand, and (CYP3A4*1B R5) 5’-
TCAGAAACTCAAGTGGAGCC-3’ for the reverse strand. 
For the CYP3A5*3C allele, primers were designed and chosen as follows: (5’-
TCCTCAGAATCCACAGCGCTG-3’ (CYP3A5*3C F1) and 5’-
TTTATGTGCTGGAGAAGGACG-3’ (CYP3A5*3C R1). These primers were used in a 20 µL 
reaction that contained 1× PCR buffer (Perkin-Elmer), 1.5 mM MgCl2, 2 mM dNTPs, and 2 
units of Platinum Taq polymerase (Invitrogen). The cycle conditions were: one cycle at 
94oC for 5 minutes, followed by 20 cycles of 94oC for 30 seconds, 64oC for 30 seconds, 
and 72oC for 30 seconds, ending with a final 7-minute cycle at 72oC. After initial 
amplification, 3 µL of amplified product was removed and an additional PCR 
amplification (as described above in a total of 50 µL final volume) was performed using 40 
pmol of primers 5’-AGCACTTGATGATTTACCTGCC-3’ (CYP3A5*3C F2) and 5’-
CCAGGAAGCCAGACTTTGATC-3’ (CYP3A5*3C R2). PCR conditions for this reaction 
were 94oC for 5 minutes, followed by 40 cycles of 94oC for 30 seconds, 62oC for 30 
seconds, and 72oC for 30 seconds, with a final 7-minute cycle at 72oC. Sequencing 
primers were as follows: (CYP3A5*3C F3) 5’-AGTGGCATAGGAGATACCCAC-3’ and 
(CYP3A5*3C R3) 5’-AGGTTCTAGTTCATTAGGGTG-3’. 
For the CYP3A5*6 allele, an initial PCR was performed using the sample DNA and 
20 pmol of each primer, 5’-AGGGAGTAGATGGAAGATGATTC-3’ (CYP3A5*6 F1) and 5’-
AGTTGATTATTGGATGCTTAGGGC-3’ (CYP3A5*6 R1). These primers were used in the 
initial reaction along with 1× PCR buffer (Perkin-Elmer), 1.5 mM MgCl2, 2mM dNTPs, and 
2 units of Platinum Taq polymerase (Invitrogen) in a reaction volume of 20 µL. The 
temperature profile for the PCR reaction was one cycle at 94oC for 5 minutes, 40 cycles of 
94oC for 30 seconds, 64oC for 30 seconds, and 72oC for 30 seconds, followed by a final 7-
minute cycle at 72oC. After initial amplification, 3 µL of amplified product was removed 
and an additional PCR amplification using the above reaction ingredients was performed 
using 40 pmol of the designed primers 5’-TGCTGCATGTATAGTGGAAGGAC-3’ 
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(CYP3A5*6 F2) and 5’-TTTGTGGTGGGGTGTTGACAGC-3’ (CYP3A5*6 R2). PCR 
conditions for this reaction were 94oC for 5 minutes, followed by 40 cycles of 94oC for 30 
seconds, 66oC for 30 seconds, and 72oC for 30 seconds, with a final 7-minute cycle at 
72oC. The sequencing primers were 5’-TTGGGGCCTACAGCATGGATG-3’ (CYP3A5*6 
F3) and 5’-TGTGTGAGGGCTCTAGATTGAC-3’ (CYP3A5*6 R3). The existence of each 
variant was determined by direct nucleotide sequencing using the dRhodamine 
Terminator Cycle Sequencing Ready Reaction kit on an ABI 310 genetic analyzer (Applied 
Biosystems, Foster City, CA). Concordance in results between RFLP and direct sequence 
analysis was observed in all but one sample (for CYP3A5*3C only); results from sequence 
analysis were used for correlation with midazolam pharmacokinetic parameters. 
 
ABCB1 (MDR1) Genotype Analysis 
 The following primers were designed for the ABCB1 3435C>T variant in exon 26: 
5’-AGCAACCTTACATCTACTAC-3’ (ABCB1 3435C>T 6 F) and 5’- 
GGAGAGACAGTCATGCCTAC-3’ (ABCB1 3435C>T R), and nested primers 5’- 
TCACAGTAACTTGGCAGTTTCA 3’ (ABCB1 3435C>T F) and 5’- 
GGGACCAGCCCCTTATAAATC 3’ (ABCB1 3435C>T R) (Invitrogen). The outside primers 
and approximately 100 ng of genomic DNA were added to a 15-µL reaction mixture 
consisting of 1 mM dNTPs, 1× PCR buffer, 2.5 mM MgCl2 and 0.6 units of Amplitaq Gold 
(Applied Biosystems). For the nested PCR reaction, 2 µL of the first PCR product was used 
as template for amplification. The thermocycler conditions were: an initial cycle at 95°C 
for 12 minutes, followed by 10 cycles 94°C for 45 seconds, 55°C for 1 minute and 72°C 
for 1 minute, 20 cycles of 89°C for 1 minute, 55°C for 1 minute and 72°C for 1 minute, 
and ending with a final 10-minute cycle at 72°C. The restriction enzyme MboI (New 
England Biolabs, Beverly, MA) was used for the determination of the variants. Enzyme (0.5 
µL) and 2 µL of enzyme buffer were added to 20 µL of PCR product and incubated at 37°C 
for 1 hour, followed by an incubation at 65°C for 20 minutes. Blue juice (1 µL of 5× 
solution) was added to 10 µL restricted PCR product, and run on a 2.0% agarose gel with 
ethidium bromide as a fluorescence detector. A “T” mutation was determined by bands of 
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408, 263, 158, 103, 59 bp; a “C” was determined by bands of 263, 236, 172, 158, 59 bp; 
heterozygous samples contained all bands. The existence of the variant was also 
determined by direct nucleotide sequencing after a cleanup step with MinElute PCR 
purification kit (Qiagen) in a total volume of 12 µL, which included 6 µL of DNA at 3 ng 
per 100 bp of amplified products and 6 µL of either the forward or reverse primer. 
Sequencing in the forward and reverse direction was performed using an ABI 3730XL 
Sequencer (Applied Biosystems). Concordance in results between RFLP and direct 
sequence analysis was observed in all but four samples; results from sequence analysis 
were used for correlation with midazolam pharmacokinetic parameters. 
 
Statistical Considerations 
All data are presented as mean values ± standard deviation (SD), unless stated 
otherwise. Genotype-frequency analysis of Hardy-Weinberg equilibrium was carried out 
using Clump version 1.9. Linkage disequilibrium was calculated using EMLD (Qiqing 
Huang; see: http://linkage.rockefeller.edu/soft/). The linkage between each pair of SNPs 
was determined in terms of the classical statistic D’. The absolute value for D’ (D’) of 1 
denotes complete linkage disequilibrium, while a value of 0 denotes complete linkage 
equilibrium.  
To relate pharmacokinetic parameters with the variant genotypes, the Kruskal-
Wallis test, a nonparametric one-way analysis of variance, was used for each 
polymorphism examined. (NCSS v2001; J. Hintze, Number Cruncher Statistical Systems, 
Kaysville, UT). Although this study was mainly exploratory in intent, a Bonferroni 
adjustment was used to evaluate the significance of the multiple comparisons. Two-sided 
P-values of less than 0.017 (0.05 divided by the three observed variant genotypes) were 
regarded as statistically significant, and those less than 0.05 were considered a trend. 
These levels were chosen to reduce the risk of finding purely coincidental associations in 
view of the number of variant genotypes analyzed concurrently. 
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Results 
Patients 
A total of 58 adult patients (21 women and 37 men) were evaluated during this 
study. Patients were of Caucasian (n = 55), African American (n = 2) or Hispanic (n = 1) 
descent, and were between 29 and 73 years old (median age, 57 years). Additional patient 
demographics are shown in Table 1. 
 
Table 1. Patient Demographics 
Gender Female: 27  
 
 Male: 31  
 
Race Caucasian 55  
 
 African-American 2  
 
 Hispanic 1  
 
     
 Mean Median Min Max 
Age (years) 56.7 58 29 73 
Height (m) 1.73 1.74 1.55 1.91 
Weight (kg) 80.27 77.85 48 137 
BSA (m2) 1.94 1.91 1.46 2.46 
Bilirubin (µg/dL) 0.50 0.47 0.23 1.23 
 
 
Midazolam Disposition 
Complete midazolam pharmacokinetic data following i.v. administration were 
available in all 58 patients. The mean dose-normalized AUC was 90.2 ± 35.8 ng×h/mL, 
whereas the mean clearance was 24.4 ± 9.12 L/h, which is consistent with earlier findings 
obtained in cancer patients following i.v. administration of midazolam [15,16]. Table 2 
provides a comparison of the clearance values determined in previously conducted trials 
in cancer patients and healthy volunteers, which involved genotyping for CYP3A5*3C.  
 
Chapter 4 
82 
 
T
ab
le 2
.  Su
m
m
a
ry o
f m
id
azo
lam
 p
h
arm
ac
o
kin
etics 
P
aram
eter 
M
e
a
n
 
M
e
d
ia
n
 
S
D
 
M
in
 
M
a
x
 
Sam
p
le Size 
P
o
p
u
latio
n
 (ro
u
te) 
A
U
C
 (n
g
!
h
/m
L) 
9
0
.2
 
8
0
.6
 
3
5
.8
 
3
9
.0
 
2
0
4
 
 
 
C
m
ax (n
g/m
l) 
7
9
.2
 
7
1
.2
 
3
1
.9
 
3
7
.5
 
1
9
4
 
 
 
V
ss (L) 
7
8
.0
 
7
0
.1
 
4
0
.1
 
2
4
.9
 
2
2
8
 
 
 
T
1
/2
, z (h
) 
3
.4
0
 
2
.8
 
2
.3
7
 
0
.6
2
 
1
7
.5
 
 
 
C
L (L/h
) 
 
 
 
 
 
 
 
T
h
is stu
d
y 
2
4
.4
 
2
2
.8
 
9
.1
2
 
1
0
.8
 
4
4
.3
 
5
8
 
C
an
cer p
atien
ts (IV
) 
R
ef [1
5
] 
2
5
.6
 
b
 
9
.8
8
 
b 
b 
3
1
 
C
an
cer p
atien
ts (IV
) 
R
ef [2
8
] 
3
4
.9
 a 
b
 
b 
b 
b 
2
2
 
C
Y
P
3
A
5
*
3
C
/3
C
 vo
lu
n
teers (P
O
)  
 
3
1
.9
 a 
b
 
b 
b 
b 
1
7
 
C
Y
P
3
A
5
*
1
A
/
*
3
C
 vo
lu
n
teers (P
O
) 
R
ef [4
2
] 
2
5
.4
 
b
 
9
.3
 
b 
b 
2
7
 
C
an
cer p
atien
ts (IV
) 
 
2
4
.4
 
b
 
8
.1
 
b 
b 
2
4
 
V
o
lu
n
teers (IV
) 
R
ef [2
5
] 
2
3
.2
 
b
 
6
.3
 
9
 
4
7
.6
 
2
3
 
V
o
lu
n
teers (IV
) 
R
ef [2
4
] 
1
1
2
 a 
1
2
3
a 
b 
5
5
.6
 
2
1
4
 
2
1
 
V
o
lu
n
teers (P
O
) 
R
ef [1
6
] 
2
6
.9
 
b
 
1
2
.8
 
8
.7
 
6
8
.7
 
4
5
 
C
an
cer p
atien
ts (IV
) 
 
8
1
.7
 
b
 
4
1
.5
 
7
.7
4
 
1
8
5
 
2
2
 
C
an
cer p
atien
ts (P
O
) 
R
ef [2
9
] 
3
2
.5
 
b
 
1
0
.2
 
b 
b 
6
 
C
Y
P
3
A
5
*
1
A
/
*
1
A
 vo
lu
n
teers (IV
) 
 
3
2
.1
 
b
 
1
4
.5
 
b 
b 
6
 
C
Y
P
3
A
5
*
1
A
/
*
3
C
 vo
lu
n
teers (IV
) 
 
2
8
.4
 
b
 
1
2
.5
 
b 
b 
7
 
C
Y
P
3
A
5
*
3
C
/
*
3
C
 vo
lu
n
teers (IV
) 
A
b
b
re
v
ia
tio
n
s: A
U
C
, d
o
se
-n
o
rm
a
lized
 area
 u
n
d
er th
e
 p
lasm
a
 c
o
n
c
en
tratio
n
 versu
s tim
e
 c
u
rve
 e
xtra
p
o
lated
 to
 in
fin
ity; C
m
ax, d
o
se-n
o
rm
aliz
ed
 p
ea
k 
p
la
sm
a
 c
o
n
c
en
tratio
n; V
ss , v
o
lu
m
e
 o
f d
istrib
u
tio
n
 at stead
y-state; T
1
/2
,z, h
alf-life o
f th
e
 te
rm
in
al p
h
ase; C
L, clearan
c
e o
r a
p
p
a
re
nt o
ral clearan
ce
 (C
L/F) 
in
 ca
se o
f oral ad
m
in
istratio
n. a C
alcu
lated
 b
ased
 o
n
 A
U
C
 an
d
 d
o
se p
u
b
lish
e
d. b D
ata n
o
t p
ro
vid
ed
. 
 
Impact of CYP3A genotype on midazolam PK 
83 
Variant Genotypes 
Genotyping results were available for all patients except for CYP3A4*1B, which 
had available data for 57 of the 58 patients (Table 3). Of these 57 patients, there were six 
carriers of the CYP3A4*1B allele (five heterozygous CYP3A4*1A/*1B, and one 
homozygous CYP3A4*1B/*1B). Both of the subjects of African-American descent were 
wild-type for CYP3A4*1B (homozygous CYP3A4*1A/*1A). No patients were identified 
carrying variant alleles for CYP3A4*17, CYP3A4*18A, or CYP3A5*6. Forty-eight of the 58 
patients were homozygous variants for CYP3A5*3C and there were eight heterozygotes 
(CYP3A5*1A/*3C). The ABCB1 3435C>T genotypes were distributed as follows: wild-type 
(C/C), 12; heterozygous (C/T), 35; and variant (T/T), 11. 
ABCB1 3435C>T was in linkage equilibrium with both CYP3A4*1B and 
CYP3A5*3C (D’ = 0.183 and 0.0933, respectively). Linkage disequilibrium was apparent 
between CYP3A4*1B and CYP3A5*3C, (D’ = 0.656), as described previously [17].  
 
Genotype-Phenotype Relations 
There were no significant correlations between any of the variant genotypes and 
clearance, volume of distribution at steady-state, or AUC (Figure 1 and Table 4). Although 
the mean midazolam clearance was 1.2 times higher in patients with the CYP3A5*1A/*1A 
genotype compared with patients that were homozygous variant (CYP3A5*3C/*3C), this 
difference was not statistically significant (P = 0.50). Furthermore, there was no correlation 
between CYP3A5*3C genotype status and clearance, when patients with the homozygous 
variant genotype (CYP3A5*3C/*3C) were compared with patients that had at least one 
wild-type allele (CYP3A5*1A/*1A and CYP3A5*1A/*3C) (P = 0.24).  
 
Comparison of Predicted and Observed AUC 
The AUC of midazolam was also calculated with a limited-sampling model based 
on the 4-hour time point, as done by Wong et al. [16]. This model was designed originally 
using a different data set, as described elsewhere [12]. Figure 2 shows the correlation of 
the observed AUC with the calculated AUC. The correlation between the predicted AUC  
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and the observed AUC, using all time points, showed an R2 = 0.749. The mean (± standard 
error) bias and precision of the prediction made by the model, determined by calculation 
of the percentage mean prediction error and the relative root mean squared prediction 
error, were -18.3 ± 5.82% and 30.2 ± 3.73%, respectively. 
 
Discussion 
Interindividual variability in drug efficacy and toxicity, resulting in unpredictable 
patient responses, is commonly observed in all therapeutic areas [18]. However, these 
differences are particularly important in the field of cancer therapy since many anticancer 
agents have a narrow therapeutic index. It is now well recognized that, in addition to 
environmental and physiological factors, such interpatient variation is commonly 
associated with polymorphisms in genes encoding drug metabolizing enzymes, drug 
transporters, and/or drug targets. In this study, we tested the hypothesis that the disposition 
of the prototypical CYP3A substrate drug midazolam in cancer patients is dependent on 
genetic variability in the CYP3A4 and CYP3A5 genes.  
It has been proposed that genotyping for CYP3A4 and CYP3A5 variants may be 
useful for prediction of total CYP3A activity because of the genetic diversity in the genes 
encoding these proteins [2,3]. Over 30 SNPs in CYP3A4 have been published; however, 
most are unlikely to contribute substantially to the interindividual variability of CYP3A4 
activity in vivo, based on their limited functional significance and/or low allele frequency 
[3,19,20]. Similar to earlier findings [21], the very low allele frequency of the functional 
CYP3A4*17 and CYP3A4*18A variants evaluated in the present study suggests that these 
SNPs most likely have no broad relevance to CYP3A4 activity and function in 
predominantly Caucasian populations. The one additional SNP that was studied here, 
CYP3A4*1B, is a promoter variant in the so-called nifedipine-specific element. The allele 
frequency of this variant is known to depend on racial ancestry, being absent in Japanese 
and Chinese subjects, and present in 2 to 10% in Caucasians, and 35 to 67% in African 
Americans, respectively [3]. The currently observed frequency of 6.1% is consistent with 
previous estimates for predominantly Caucasian populations. Although the functional 
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Fig. 1. Midazolam clearance as a function of the CYP3A4*1B, CYP3A5*3C, and ABCB1 
3435C>T genotypes. Horizontal lines indicate mean values in each group. Wt, 
Homozygous wild-type patient; Het, Heterozygous patient; Var, Homozygous variant 
patient. Two-sided P-values are given above the panels 
 
 
significance of this SNP presently remains unclear, the preponderance of the evidence 
suggests that CYP3A4*1B does not affect the metabolism and clearance of CYP3A4 
substrate drugs [22-26]. Likewise, in the current study the pharmacokinetic profile of 
midazolam was not significantly different between patients with or without the 
CYP3A4*1B variant allele. 
As mentioned previously, and in contrast to CYP3A4, the CYP3A5 protein isoform 
is known to be expressed in only a small percentage of Caucasian individuals, and this has 
been linked to a common transition in intron 3 of the CYP3A5 gene (CYP3A5*3C), which 
introduces a frameshift during translation and results in a truncated, nonfunctional protein 
[4,5].  Approximately 70 to 90% of Caucasian subjects are homozygous variant for 
CYP3A5*3C, and thus are deficient in functionally active CYP3A5 [27], which is 
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consistent with the currently observed genotype frequency of 89.7%. In the present study, 
no change in midazolam pharmacokinetic parameters was noted between ten patients 
with at least one wild-type (CYP3A5*1A) allele and 48 patients carrying two variant 
(CYP3A5*3C) alleles. This is similar to findings obtained in healthy subjects using 
midazolam [24,25,28,29], or various other CYP3A phenotyping probes, including 
erythromycin [23,25], and nifedipine [30]. Interestingly, in a small cohort of Australian 
cancer patients, Wong et al. recently observed approximately 1.4-fold higher systemic 
clearance of midazolam in four patients with the CYP3A5*1A/*3C genotype compared to 
39 patients with the CYP3A5*3C/*3C genotype (P = 0.01) [16]. In an effort to explain this 
discrepant finding, it is noteworthy that the interindividual variability in CYP3A 
phenotypic activity was substantially greater in the study reported by Wong et al. than that 
found in the various other studies [8-fold for systemic clearance and 24-fold for apparent 
oral clearance [16] versus 3.3-fold to 5.2-fold [24,25,28,29]], suggesting the possibility of 
altered expression of either CYP3A4, CYP3A5, or both, as a result of differences in 
advancement of the disease state of patients in the studied cohort [31]. 
Wong et al. estimated the systemic midazolam clearance from a previously 
developed limited-sampling model, based on the collection of one plasma sample 
obtained 4 hours after drug administration [16]. Although a retrospective validation of this 
model on our own data set indicated a good correlation between the predicted AUC and 
the observed AUC (R2 = 0.749), the model had a statistically significant tendency for 
systematic negative error and demonstrated poor precision. To illustrate this problem, two 
different patients in our cohort that had very similar observed AUC values of 117.0 and 
117.2 ng×h/mL, respectively, had a predicted AUC based on the limited-sampling model 
of 37.3 and 165 ng×h/mL, respectively. This raises the possibility that some of the 
proposed genotype-phenotype associations described previously that were based on 
parameter estimates from a limited-sampling model might be particularly prone to the risk 
of false-positive error due to inaccurate phenotypic assessments. In addition, some error 
may also be attributed to the smaller sample size used in the previous study [16]. 
Collectively, current evidence does not suggest that CYP3A5*3C-associated differences in  
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the extent of drug metabolism of CYP3A substrates are clinically important. 
The extent to which the CYP3A isoforms metabolize midazolam is likely to be 
determined, at least in part, by intracellular drug concentrations in the liver and, to a 
lesser extent, the intestine. This process, in turn, is partially dependent on the ATP-binding 
cassette transporters like ABCB1 (P-glycoprotein) that are localized in the apical 
membrane of hepatocytes and enterocytes. Although it has been suggested that 
midazolam is not a substrate for ABCB1 [32], recent data have indicated that midazolam 
exhibits characteristics of a highly permeable ABCB1 substrate [33]. The clearance of 
midazolam has also been shown to be correlated (R2 = 0.6; P = 0.0005) with the clearance 
of docetaxel [15], a known dual substrate of CYP3A and ABCB1 [34], suggesting that 
varying expression of ABCB1 may alter midazolam clearance. In recent years, various 
genetic variants in the ABCB1 gene have been described that may impact transporter 
expression or function [35]. The most extensively studied ABCB1 variant to date is a 
common synonymous C to T transition at nucleotide position 3435 at a wobble position in 
exon 26 [36]. Although this transition does not change its encoded amino acid, recent 
findings have indicated that this variant is associated with altered protein expression in 
different human tissues [37], and this may result in decreased hepatobiliary and/or 
intestinal secretion of substrate drugs. Furthermore, a reduced expression of intestinal 
CYP3A4 mRNA has been observed in subjects carrying the homozygous variant genotype 
of the ABCB1 3435C>T polymorphism in a Japanese population [38], further pointing to 
the possibility of ABCB1 genotype affecting midazolam clearance. However, in this study, 
midazolam pharmacokinetic parameters were not significantly influenced by the ABCB1 
3435C>T genotype, which is consistent with prior observations in healthy volunteers 
[25,39]. It should be noted that the lack of relationships with this SNP is, as expected, 
consistent with preclinical observations in Abcb1a-deficient mice that metabolism rather 
than transport is the prominent elimination pathway for midazolam [40]. This further 
suggests that the involvement of ABCB1 in the disposition of midazolam may be relatively 
unimportant regardless of ABCB1 genotype status. 
The lack of statistically significant relations in this study does not necessarily mean 
that there are none, especially in light of the few individuals studied in our population.   
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Fig 2. Scatter plot of the observed area under the curve (AUC) of midazolam versus the 
AUC of midazolam calculated based on the observed midazolam concentration at the 4-
hour sampling time point (4-h conc.) using the limited sampling model equation: AUC = 
9.91 + 12.2 × [4-h conc.], as described previously [12]. The dotted line indicates a linear 
regression fit, whereas the solid line represents the line of identity. 
 
with a homozygous variant genotype. However, the variant genotype effects are minor 
and/or the genotype heterogeneity is sufficiently small to conclude that the presently 
studied variants in the CYP3A4 and CYP3A5 genes do not cause a substantial 
interindividual difference in midazolam clearance and, thus, are unlikely to have an 
important functional significance in cancer patients treated with CYP3A substrate drugs. 
For example, even in a population of this size, if CYP3A5 genotype accounted for the 
large degree of variability in midazolam pharmacokinetics, detection of this effect would 
have been expected.  
There may be a number of other factors contributing to the variability in 
midazolam pharmacokinetics, since the tested genetic variants do not appear to explain 
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this finding. A recent study has shown an inverse correlation between liver dysfunction, 
particularly total bilirubin levels, and CYP3A activity [23]. Though all participants in the 
current study had total bilirubin levels within 1.5 times the upper limit of normal, there 
was still a considerable range represented (Table 1). Inflammatory response in patients 
with cancer, resulting in increased α-1 acid glycoprotein serum concentrations, has also 
been suggested to decrease clearance by the CYP3A isozymes [41]. Age and sex have also 
been postulated to influence CYP3A activity. Furthermore, many drugs and herbal 
medications are known to interact with CYP3A. Though patients were asked to abstain 
from any drugs known to affect the function and/or expression of either CYP3A or ABCB1, 
this possibility cannot be entirely excluded. Finally, it is possible that additional genes, 
genetic variants and/or haplotypes of importance to the pharmacokinetics of CYP3A 
substrate drugs like midazolam may yet be discovered and/or evaluated. Further 
investigation is needed to determine the relative role of genetic variation and 
environmental variables (e.g., concomitant drugs or herbs) on the pharmacokinetics of 
anticancer drugs that are substrates of CYP3A4 and CYP3A5. 
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Abstract 
Purpose: Imatinib, a tyrosine kinase inhibitor currently approved for treatment of several 
malignancies, has been shown to be a substrate for multiple efflux-transporter proteins, 
including ABCB1 (P-glycoprotein) and ABCG2 (BCRP). The effect of inhibiting these 
transporters on tissue exposure to imatinib remains unclear. 
Methods: To assess the role of these transporters on drug disposition, 50 mg/kg imatinib 
was administered to Balb/C mice, 30 minutes after receiving tariquidar (10 mg/kg), an 
inhibitor of both ABCB1 and ABCG2, or vehicle, via oral gavage.  Quantitative 
determination of imatinib in mouse plasma, liver and brain was performed using a newly-
developed and validated liquid-chromatography-mass spectrometric method.   
Results: Exposure to imatinib was 2.2-fold higher in plasma, liver and brain in mice that 
received tariquidar, as compared to those that received the vehicle (P = 0.001).  The peak 
plasma concentration did not increase substantially, suggesting that tariquidar is affecting 
the distribution, metabolism and/or excretion of imatinib, rather than absorption. Though 
tariquidar increased the absolute exposure of imatinib, the brain-to-plasma ratio of 
imatinib was unaffected.   
Conclusions: This study suggests that intentional inhibition of ABCB1 and ABCG2 function 
at the blood-brain barrier is unlikely to significantly improve clinical outcome of imatinib 
with currently used dosing regimens. 
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Introduction 
Imatinib mesylate is an orally administered tyrosine kinase inhibitor, currently FDA 
approved for the treatment of Philadelphia chromosome-positive chronic myeloid 
leukemia (targeting Brc-Abl) and unresectable and/or metastatic malignant gastrointestinal 
stromal tumors (targeting c-KIT) [1].  This agent is also currently under intensive 
investigation in other tumor types, most notably as a single agent or in combination with 
hydroxyurea for the treatment of gliomas.  However, there has been limited clinical 
success in brain tumors reported to date [2,3]. 
Imatinib was initially determined to be a substrate for ABCB1 (P-glycoprotein) in 
vitro [4].  Subsequently, it was demonstrated that the in vivo distribution of imatinib is 
limited by ABCB1-mediated efflux, resulting in limited brain penetration [5].  More 
recently, positron emission topography studies with [N-11C-methyl]-imatinib have 
confirmed limited brain penetration in primates [6].  However, ABCB1 is not the sole 
transporter expressed in the blood-brain barrier that may limit the brain distribution of 
imatinib.  In particular, imatinib is both an inhibitor [7] and substrate [8] of ABCG2 
(BCRP). Experiments comparing the plasma and brain pharmacokinetics of imatinib 
following i.v. administration of radiolabeled drug to wild-type, Abcb1 knockout and 
Abcg2 knockout mice have confirmed a role of these transporter proteins in limiting brain 
exposure [9]. 
The potential influence of these efflux transporters is not limited to brain exposure.  
For example, ABCB1 and ABCG2 are also highly expressed in the small intestine, bile 
canaliculi of the liver and numerous other normal tissues [10,11].  In addition, expression 
of these proteins in human tumors has been associated with development of multidrug 
resistance [12]. Furthermore, in vitro studies have suggested that long-term treatment with 
imatinib leads to increased expression of both ABCB1 and ABCG2, resulting in decreased 
intracellular drug accumulation [13].  As such, it is of great interest to identify and 
characterize inhibitors of ABCB1 and ABCG2 in vivo that could potentially be used to 
intentionally alter the pharmacokinetics of and/or improve response to therapy with 
anticancer ABCB1 and ABCG2 substrates [11]. 
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Several transporter inhibitors have previously been evaluated in preclinical models, 
including the ABCB1 inhibitors valspodar and zosuquidar, the ABCG2 inhibitor 
pantoprazol and the dual ABCB1/ABCG2 inhibitor elacridar [9,14].  Tariquidar, an orally 
available anthranilic acid derivative, has been shown to be an inhibitor of both ABCB1 
and ABCG2 [15].  It is currently in clinical trials evaluating its utility as an inhibitor of 
ABCB1, in an effort to overcome resistance associated with anticancer chemotherapy [16].  
Here, we evaluated the effect of tariquidar on the disposition of imatinib in mice, in order 
to provide a pharmacokinetic rationale for attempts to improve the agent’s low brain 
penetration. 
 
Materials and Methods 
Chemicals and reagents 
Imatinib mesylate was supplied by Novartis (East Hanover, NJ).  Tariquidar was 
supplied by Dr. Susan Bates (NCI, Bethesda, MD).  Glucose, harmine, absolute ethanol 
and ammonium acetate were purchased from Sigma-Aldrich (St. Louis, MO).  Formic acid 
(98%) was obtained from Fluka (through Sigma-Aldrich).  Methanol (J.T. Baker, 
Phillipsburg, NJ) was of HPLC grade.  Deionized water was generated with a Hydro-
Reverse Osmosis system (Durham, NC) connected to a Milli-Q UV Plus purifying system 
(Billerica, MA).  Blank mouse plasma was purchased from Innovative Research 
(Southfield, MI). 
 
Sample preparation 
Unknown and quality control (QC) plasma samples were thawed at room 
temperature, vortex mixed for 20 seconds, and 100 µL were transferred to a polypropylene 
centrifuge tube.  For analysis of unknown tissue samples, approximately 100 mg of tissue 
were accurately weighed and water added (5 µL per mg).  After vortex-mixing, samples 
were homogenized using a PowerGen 125, while kept on ice. One hundred µL of 
homogenate was transferred to a clean polypropylene centrifuge tube for further 
processing.  To each tube, including calibrators (10, 25, 50, 100, 500 and 1000 ng/mL) 
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and QC samples (30, 450, 800 and 18,000 ng/mL), 250 µL of methanol (containing 25 
ng/mL of internal standard, harmine) was added.  All tubes were capped, vortex-mixed for 
5 min and then centrifuged for 5 min at 18,000 x g.  Following centrifugation, the 
supernatant was transferred to a vial for injection.  Either 5 or 10 µL of the supernatant was 
injected for tissue or plasma samples, respectively. Calibration curves and QC samples 
were prepared in both brain and liver, for tissue sample analysis.The working ranges for 
liver and brain were 0.125-100 and 0.125-25 ng/mL, respectively.  
 
Equipment  
High performance liquid chromatography was carried out on an Agilent 1100 
system (Agilent Technology, Palo Alto, CA), coupled with a single-quadrupole mass 
spectrometer, utilizing electrospray ionization in positive mode.  Samples were cooled to 
4 °C in a thermostated autosampler and the column compartment, containing a Waters 
SymmetryShield RP8 column (2.1 x 50 mm, 3.5 µm), was maintained at 35 °C.  Samples 
were eluted using a gradient mobile phase, comprised of 10 mM ammonium acetate with 
0.1% formic acid and methanol, running at a flow rate of 0.35 mL/min for 10 min, 
including re-equilibration.  Mass spectrometric conditions were as follows: fragmentor, 
150 V; gain, 2; drying gas flow, 10 L/min; drying gas temperature, 300 °C; nebulizer 
pressure, 40 psi; and capillary voltage, 1500 V.  Selected-ion monitoring was 
accomplished at m/z 494.2 for imatinib and m/z 213.1 for the internal standard.  The 
chromatographic data were acquired and analyzed using the Chemstation software 
package (Agilent). 
 
Validation procedures 
Calculation of accuracy and precision was carried out according to procedures 
reported in detail previously [17].  Calibration samples were prepared fresh each day in 
the relevant matrix and frozen QC samples were defrosted and analyzed.  A 1/x2 
weighting scheme was employed in the generation of standard curves to account for 
concentration dependent variance.  Detector response for plasma was found to be linear 
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in the imatinib concentration range of 10-1000 ng/mL.  Plasma accuracy and precision 
were evaluated with QC samples.  Overall, the assay was found to be accurate (deviation 
of less than 10% for QCs) and precise (within run precision <10%, between run precision 
<12.6%) for plasma, liver, and brain. 
 
Animals 
All experiments were performed on six-week old, male, Balb/C mice obtained from 
Charles River Laboratories (Wilmington, MA).  The mice weighed approximately 15 to 20 
g at the time of study. All mice were allowed unlimited access to water and rodent chow 
prior to, and during the experiment. Blank mouse liver and brain samples were harvested 
from surplus mice following euthanasia. NCI-Frederick is accredited by AAALAC 
International and follows the Public Health Service Policy for the Care and Use of 
Laboratory Animals.  Animal care was provided in accordance with the procedures 
outlined in the "Guide for Care and Use of Laboratory Animals" (National Research 
Council; 1996; National Academy Press; Washington, DC).  The study design and 
protocol were approved by the NCI Animal Care and Use Committee (Bethesda, MD). 
 
Experimental design 
Imatinib was dissolved in sterile water to make a 10 mg/mL dosing solution.  
Tariquidar was prepared as a 2 mg/mL solution in water with 5% glucose.  Mice received 
either 10 mg/kg tariquidar or the vehicle (5 mL per kg weight) [15] 30 minutes prior to 50 
mg/kg of imatinib [18].  All compounds were administered via oral gavage. At each time 
point, three mice in each treatment group were anesthetized with isoflurane, and bled via 
cardiac puncture into a tube containing sodium heparin as an anticoagulant.  Blood 
samples were centrifuged at 18,000 x g for 5 minutes at 4 °C, the plasma layer transferred 
to a cryovial and frozen.  Following euthanasia by cervical dislocation, brain and liver 
tissues were excised and snap-frozen.  All samples were stored at -80 °C until the time of 
analysis. 
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Statistical and pharmacokinetic analysis  
Concentration-time data were evaluated using a non-compartmental approach, 
with WinNonlin 5.0 (Pharsight, Mountain View, CA), using the mean concentration (n=3) 
at each time point.  The peak plasma concentration (Cmax) and the time to peak plasma 
concentration (Tmax) are reported as observed values.   The area under the curve (AUC) 
was calculated using the linear trapezoidal method from time zero to the time of the last 
sample with measurable drug concentration.  To allow for direct comparison between the 
two groups and characterization of the terminal phase for the imatinib alone arm, the 24-
hour plasma and liver samples, along with the 4-hour brain samples were estimated at 
LLQ/2, as drug was detectable, but measured concentrations were below the limit of 
quantitation.  Bailer’s method was employed to assess the variance, allowing for 
comparison of exposure between the two dose groups.  The significance of the difference 
in AUC was evaluated by a Z-test.  Brain concentrations were corrected for drug in the 
brain vascular space, by subtracting 1.4% of the plasma concentration from the measured 
brain concentration for each animal [5].  Brain-to-plasma concentration ratios were 
calculated for each animal at the 2-hour time point, and the groups compared using a t-
test.  All statistical tests were performed in Microsoft Excel 2004 (Redmond, WA). P-values 
<0.05 were considered significant. 
 
Results 
The administration of oral tariquidar 30 minutes prior to an oral dose of imatinib 
resulted in a significant increase in systemic exposure to imatinib (Table 1; Figure 1).  
Tariquidar increased the peak plasma concentration of imatinib by 19% (6,813 ± 1,548 vs 
5,711 ± 1,472 ng/mL, P = ns), with no apparent change in the rate of absorption, as 
judged from the similar times to peak concentration (0.17 hours).  In contrast, the AUC0-24 
for imatinib was 2.2-fold higher in mice pretreated with tariquidar compared to the 
vehicle (26,725 vs 12,168 hr*ng/mL, P = 0.001).  In liver tissue, tariquidar increased the 
peak concentration by 75% (46,139 vs 26,280 ng/g) and the AUC0-24 was also 2.2-fold 
higher (153,209 vs 68,331 hr*ng/mL, P < 0.00001).  The maximal corrected concentration  
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Table 1. Pharmacokinetics of imatinib in Balb/C mice in the presence and 
absence of tariquidar 
 Imatinib Imatinib + Tariquidar 
 
Plasma Mean SD Mean SD P-value 
Cmax (ng/mL) 5710.5 1472.3 6813.2 1547.9 - 
Tmax 
(hr) 
0.17 - 0.17 - - 
AUC0-24 
(hr*ng/mL) 
12167.5 - 26724.6 - 0.001 
Liver Mean SD Mean SD P-value 
Cmax 
(ng/g) 
26279.7 4560.2 46139.1 11000.6 - 
Tmax 
(hr) 
0.25 - 0.17 - - 
AUC0-24 
(hr*ng/g) 
68330.8 - 153209.2 - <0.00001 
Brain Mean SD Mean SD P-value 
Cmax 
(ng/g) 
194.7 27.2 417.0 116.6 - 
Tmax 
(hr) 
2 - 
2 
 
- - 
AUC0-4 
(hr*ng/g) 
574.23 - 1277.7 - 0.00001 
 
of imatinib achieved in brain tissue was 114% higher in the imatinib plus tariquidar group 
(417 vs 195 ng/g), and the AUC0-4 was 2.2-fold higher (417 vs 195 hr*ng/mL, P = 
0.00002).  No imatinib was detectable in the brain within the first 5 minutes after 
administration in either group, and the maximal brain concentration was observed after 
two hours in both groups.  The brain-to-plasma ratio of imatinib 2 hours after 
administration did not differ significantly between the two groups (P = 0.83), and similar 
brain-to-plasma AUC0-4 ratios were observed for each group (0.070 for imatinib plus 
vehicle versus 0.078 for imatinib plus tariquidar). In addition, the liver-to-plasma AUC0-24 
ratios did not differ significantly between the two groups. 
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Conclusions 
The current study indicates that administration of the dual ABCB1 and ABCG2 
inhibitor tariquidar results in a statistically significantly increase in plasma, liver and brain 
exposure to imatinib.  Since imatinib is known to have very high bioavailability 
(approximately 98%) [1], it is likely that the difference in plasma AUC is due to modified 
distribution and/or elimination of the drug, rather than a change in the extent of intestinal 
absorption.  This hypothesis is supported by the fact that tariquidar increased the peak 
plasma concentration of imatinib by less than 20% and this change was not statistically 
significant. As expected, there was also no apparent change in the rate of absorption. 
Considering that imatinib is effluxed by both ABCB1 and ABCG2, the almost complete 
bioavailability may seem somewhat surprising. However, it is possible that the high 
concentrations of imatinib in the gut are actually leading to localized inhibition of these 
transporters, as has been suggested by inhibition data [7].  
Inhibition of ABCB1 and ABCG2 by tariquidar may also alter the extent of imatinib 
metabolism.  Bihorel et al. noted an increase in plasma concentrations of imatinib 
metabolites in both Abcb1a/1b knockout and Abcg2 knockout mice; however, co-
administration of elacridar, another dual ABCB1 and ABCG2 inhibitor, did not alter the 
concentrations of imatinib metabolites [14].  Therefore, it is unclear whether this 
observation may arise due to a compensatory mechanism in the knockout mice.  
The brain-to-plasma concentration ratio of imatinib 2 hours after administration 
was not significantly affected by tariquidar.  In addition, the AUC0-4 ratio for brain-to-
plasma was similar in the presence or absence of tariquidar.  This suggests that, rather 
than modifying the blood-brain barrier directly, tariquidar may simply be increasing 
plasma concentrations of the drug, leading to saturation of these efflux transporters at this 
site.  The AUCs of imatinib in plasma and both of the tissues studied were 2.2-fold higher 
following pre-treatment with tariquidar.  If modulation at the blood-brain barrier were 
occurring, independent of increased plasma concentrations of drug, it was hypothesized 
that the brain accumulation would be greater, not merely the same, as the increase in 
plasma.  
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Figure 1. Concentration-time profiles of imatinib in A. plasma, B. liver and C. brain, for the 
imatinib plus vehicle group (solid line) and the imatinib plus tariquidar group (dashed line). 
Error bars for each timepoint represent the standard error.  
 
 
 
Initial comparison of the inhibitory effects of tariquidar toward ABCB1 and ABCG2, 
as compared to elacridar, in the context of imatinib disposition, may suggest that 
tariquidar is less potent, in spite of previously published data that supports the opposite 
[19].  Specifically, elacridar has been shown to result in a 9.3-fold increase in the brain-to-
plasma concentration ratio, as compared to administration of imatinib alone [14].  
However, those experiments utilized significantly lower doses of imatinib as compared to 
the present study (12.5 versus 50 mg/kg), and the absolute concentrations of drug in brain 
were not stated.  Hence, it is possible that the higher imatinib dose utilized in the current 
study results in higher plasma concentrations of drug and, therefore, saturation of drug 
efflux at the blood-brain barrier.  In this context, it is particularly noteworthy that single 
dose plasma pharmacokinetics of imatinib in humans at the recommended oral dose of 
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400 mg per day results in overall drug exposure that is very similar to that found in the 
current study for mice (24.8 ± 7.4 versus 26.3 ± 4.6 h*µg/mL) [1]. 
Direct comparison between this study and prior experiments investigating the effect 
of ABC transporter inhibitors on imatinib pharmacokinetics are difficult due to a variety of 
reasons. The current study employed oral dosing at 50 mg/kg of imatinib, in an effort to 
closely mimic the clinical situation, whereas Breedveld et al. administered 12.5 mg/kg of 
imatinib intravenously (in combination with elacridar) [9].  These authors also examined 
the effect of oral pantoprazole on the pharmacokinetics of 100 mg/kg oral imatinib [9].  
Though the increase in brain exposure to imatinib was reported to be higher with oral 
administration, as compared to i.v., this was only measured at 4 hours post-imatinib, and 
the analysis was based only on measurement of total radioactivity.  As such, it is 
impossible to determine whether the higher radioactivity in the brain is due to the parent 
drug only or the parent drug plus metabolites.  
 Mistry et al. have demonstrated that the inhibitory effect of tariquidar on drug efflux 
in vitro persists for over two hours [15].  In healthy volunteers, a dose of 2 mg/kg i.v. or ≥ 
200 mg orally, resulted in 100% inhibition of ABCB1 in CD56+ lymphocytes for over 24 
hours.  The maximal effect was observed between 2 and 6 hours after administration of 
tariquidar. In the current study, tariquidar was administered 30 minutes prior to imatinib 
administration in an effort to ensure sufficient distribution and inhibitory effects.  
In conclusion, oral administration of tariquidar prior to oral imatinib resulted in increased 
imatinib exposure in plasma and tissues, including brain.  The increase in brain exposure 
appears to be directly related to the increase in plasma concentrations of the drug, at a 
dose comparable to that used clinically.  This further substantiates the possibility that ABC 
transporters localized in the blood brain barrier are more resistant to inhibition than at 
other tissue sites such as the intestine and liver [19]. In a clinical setting, the currently 
observed increase in plasma AUC would result in increased toxicity, as has been observed 
previously with the use of ABCB1 inhibitors [20].  One strategy that has been employed is 
dose reduction prior to combining the ABCB1 and ABCG2 substrate with the transporter 
inhibitor.  However, based on the current findings, it should be anticipated that inhibition 
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of ABCB1 and ABCG2 function at the blood-brain barrier will not result in increased brain 
penetration or improved clinical outcome. 
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Abstract 
Purpose: Chronic imatinib exposure has been shown to result in upregulation of the 
ABCB1 (P-glycoprotein) and ABCG2 (BCRP) transporters in vitro, for which imatinib is a 
substrate. This finding, along a trend towards increasing imatinib clearance over time in 
patients, has resulted in the suggestion that pharmacokinetic resistance may be 
contributing to eventual treatment failure. Here, we sought to determine the effects of 
long-term imatinib exposure on apparent oral clearance and transporter expression in 
vivo. 
Methods: Male BALB/c mice were treated daily-times 5 with oral imatinib at a dose of 50 
mg/kg for 4 consecutive weeks.  Imatinib concentrations were measured in plasma and 
liver tissue prior to treatment and following each week of dosing. Western blotting of liver 
and intestinal tissue lysates was performed to assess expression of Abcb1 and Abcg2. 
Results: Plasma and liver concentrations of imatinib did not change significantly (P > 0.1) 
over the course of treatment, suggesting that steady-state had been reached. There was no 
increase in Abcb1 or Abcg2 expression in liver samples, whereas expression of these 
transporters in intestinal samples was highly variable, and no increase was apparent. 
Conclusions: Imatinib does not appear to cause upregulation of ABC transporters in the 
hepatic and intestinal compartments in mice. These data do not support the possibility that 
autoinduction contributes to the development of resistance to imatinib. 
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Introduction 
Imatinib mesylate (Gleevec®, Glivec®) is a synthetic, small molecule tyrosine kinase 
inhibitor known to target Bcr-Abl, c-KIT and PDGFR α and β [1]. This agent is currently 
FDA approved for the treatment of Philadelphia chromosome-positive chronic myeloid 
leukemia (CML) and unresectable and/or metastatic malignant gastrointestinal stromal 
tumors (GIST). Though initial response rates to imatinib are high, clinical resistance 
develops in a large number of individuals [2]. For example, over 70% of patients with 
acute leukemia develop resistance within 3-6 months of starting treatment [2]. While 
mutations of the Bcr-Abl tyrosine kinase domain are directly responsible for many of these 
cases, there are also individuals in whom such mutations have not been detected [3]. As 
such, it has been postulated that pharmacokinetic resistance may be partly responsible for 
these cases, with drug exposure decreasing during chronic treatment. Judson et al. 
described a trend towards increasing apparent oral clearance over time in patients treated 
with imatinib, supporting this hypothesis [4]. In a group of patients with CML, significantly 
higher trough concentrations of imatinib in plasma were correlated with both cytogenic 
and molecular response [5]. Furthermore, multiple studies have demonstrated that 
intrapatient imatinib dose escalation can circumvent the resistance phenotype [6,7].  
In adults, imatinib is administered daily as a tablet, at a recommended dose of 400 
per day or higher for chronic myeloid leukemia and gastrointestinal stromal tumors. 
Pharmacokinetic studies have demonstrated that imatinib has high oral bioavailability 
(>98%), yet is extensively metabolized [1]. It has been hypothesized that chronic 
treatment with imatinib may induce expression of transporter proteins and metabolizing 
enzymes. This may result in decreased overall exposure to imatinib, by limiting drug 
absorption in the gastrointestinal tract and increasing elimination.  The two ABC 
transporter proteins implicated in this process, namely ABCB1 (P-glycoprotein, MDR1) 
and ABCG2 (BCRP, MXR) [8-10], are particularly highly expressed in the small intestine, 
and the bile canaliculi of the liver [11,12].  
A previous in vitro study, utilizing human Caco-2 cells as a model of intestinal drug 
transport, demonstrated that chronic exposure to imatinib was associated with maximal 
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induction of ABCB1 and ABCG2 after 39 days of treatment with 10 µM imatinib, showing 
5-fold and 17-fold increases in mRNA, respectively [13]. At this point, intracellular 
imatinib accumulation was shown to be 2-fold higher in treatment naïve cells as 
compared to those having been subjected to chronic drug treatment. To determine 
whether this phenomenon is occurring in vivo and contributes to drug resistance, we 
assessed plasma concentrations of imatinib along with intestinal and liver expression of 
Abcb1 and Abcg2 during long-term treatment with imatinib in mice. 
 
Materials and Methods 
Chemicals and reagents   
Imatinib mesylate was supplied by Novartis (East Hanover, NJ).  Harmine, absolute 
ethanol, ammonium acetate, and sodium deoxycholate were each purchased from Sigma-
Aldrich (St. Louis, MO).  Formic acid (98%) was obtained from Fluka (through Sigma-
Aldrich).  Methanol (J.T. Baker, Phillipsburg, NJ) was of HPLC grade.  Deionized water 
was generated with a Hydro-Reverse Osmosis system (Durham, NC) connected to a Milli-
Q UV Plus purifying system (Billerica, MA). 10X TBS, 1M Tris-HCl, 5 M NaCl, and 0.5 M 
EDTA and 10% SDS solutions were purchased from KD Medical (Columbia, MD). Triton 
X-100 and Complete protease inhibitor were purchased from Roche Applied Science 
(Indianapolis, IN). Blank mouse plasma was purchased from Innovative Research 
(Southfield, MI). 
 
Animals 
All experiments were performed male BALB/c mice obtained from Charles River 
Laboratories (Wilmington, MA).  The mice were weighed twice weekly. At the start of 
treatment, all mice were eight weeks old and weighed between 25 and 30 g. Blank mouse 
liver was harvested from surplus mice following euthanasia. NCI-Frederick is accredited 
by AAALAC International and follows the Public Health Service Policy for the Care and 
Use of Laboratory Animals.  Animal care was provided in accordance with the procedures 
outlined in the "Guide for Care and Use of Laboratory Animals" (National Research 
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Council; 1996; National Academy Press; Washington, DC).  The study protocol was 
approved by the NCI Animal Care and Use Committee (Bethesda, MD). 
 
Experimental design 
Imatinib was dissolved in sodium citrate buffer (pH 3.0) to make a 10 mg/mL 
dosing solution. Three mice were sacrificed prior to the start of treatment. All remaining 
mice received 50 mg/kg of imatinib [14] once daily (5 µL of the dosing solution per g of 
body weight) via oral gavage, for five days per week for a total of 4 weeks. This dose was 
selected for its tolerability and drug exposure was expected to be comparable to that 
observed in humans [15]. Mice were weighed several times per week and dose adjusted 
for any changes in weight. Following each week of treatment, four hours after dosing, 
three mice were anesthetized with isoflurane and bled via cardiac puncture.  Blood 
samples were centrifuged at 18,000 x g for 5 minutes at 4 °C, the plasma layer transferred 
to a cryovial and frozen.  Following euthanasia by cervical dislocation, liver and intestines 
were removed and cleaned thoroughly with cold PBS (Gibco, Invitrogen, Carlsbad, CA), 
prior to snap freezing. All samples were stored at -80 °C until the time of analysis. 
 
Blood and liver sample analysis 
Plasma and liver samples were analyzed using a validated analytical assay reported 
elsewhere [15]. Briefly, 250 µL of methanol containing harmine (the internal standard) 
were added to 100 µL of the thawed plasma sample or liver homogenate (tissue 
homogenized with 5 µL/mg water using a PowerGen 125). After vortex-mixing for 5 min, 
the sample was centrifuged for 5 min at 18,000 x g.  Following centrifugation, 10 µL of the 
supernatant were injected onto a SymmetryShield column (Waters Corp, Milford, MA), 
incorporated within an Agilent 1100 system (Agilent Technology, Palo Alto, CA) that was 
coupled with a single-quadrupole mass spectrometer utilizing positive mode electrospray 
ionization and selective ion monitoring. Samples were eluted using a gradient mobile 
phase, comprised of 10 mM ammonium acetate with 0.1% formic acid and methanol, 
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running at a flow rate of 0.35 mL/min. Drug concentrations were back-calculated from 
duplicate standard curves prepared in blank mouse plasma, analyzed within the same run. 
 
Immunoblotting 
Expression of the mouse Abcb1 and Abcg2 proteins was assessed by Western blot 
analysis. Protein lysates were prepared by adding cold modified RIPA buffer (50 mM Tris-
HCL (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 5 mM EDTA and 1% 
deoxycholate) containing 1x Complete protease inhibitor to liver or intestinal tissue, while 
on ice, followed by homogenization, centrifugation and separation of the supernatant. 
Samples containing 40 µg of protein were subjected to electrophoresis on a NuPage 10% 
Bis-Tris gel with MOPS buffer (Invitrogen, Carlsbad, CA) under reducing conditions. 
Proteins were transferred electrophoretically to a PVDF membrane using the XCell II Blot 
Module (Invitrogen). Membranes were then blocked for 1 hr in 5% non-fat dried milk in 
TBST (0.1% Tween 20 in 1X TBS), followed by overnight incubation at 4° C with the 
diluted primary antibody in the milk solution. For detection of Abcg2, the rat monoclonal 
BXP-53 (Abcam, Cambridge, MA) was used as a 200-fold dilution for liver lysates and a 
100-fold dilution for intestinal lysates. For detection of Abcb1, the mouse monoclonal 
C219 (Abcam) was used as a 2000-fold dilution for liver and intestinal lysates. Mouse IgG1 
anti-β-actin (BD Transduction Laboratories, San Jose, CA) was used to confirm equal 
amounts of protein in each lane, at a dilution of 1:5000. Following extensive washing with 
TBST, and 10 min of blocking, blots were incubated with anti-rat (Abcam) or anti-mouse 
(Santa Cruz Biotechnology, Santa Cruz, CA) secondary antibodies, respectively, in milk 
solution at room temperature for 1 hr. After washing, results were visualized using the ECL 
Advanced Western Blotting Detection Kit (Amersham Biosciences, Piscataway, NJ). 
 
Statistical analysis 
Data are presented as mean ± standard deviation. Comparison between groups was 
performed using one-way ANOVA.  
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Results 
The mean 4-hr imatinib concentration in plasma after four weeks of treatment was 
445 ± 240 ng/mL, whereas the mean imatinib concentration in liver after four weeks of 
treatment was 3217 ± 1455 ng per g of tissue. There was no significant difference in 
plasma (P = 0.21) or liver (P = 0.10) concentrations between the weekly groups, 
suggesting that steady-state was reached by the end of treatment. (Figure 1). In the initial 
weeks, there was a trend towards increasing drug concentrations. Week 4 plasma 
concentrations were significantly higher than week 1. However, in contrast to the 
hypothesis that drug exposure would decrease over time with chronic treatment, no 
decline in plasma or tissue concentrations of imatinib was noted. Considering that the life 
span of a human is approximately 40 times longer than that of a BALB/c mouse, it was 
anticipated that the decline would occur rapidly during the four week experiment.  
  To assess potential changes in expression of Abcb1 and Abcg2 caused as a result of 
long-term exposure to imatinib, Western blotting of liver and intestinal tissue lysates was 
performed. There was no apparent increase in protein expression levels of either ABC 
transporter in mouse liver tissue lysates, over the four week course of treatment (Figure 2). 
In fact, there appears to be a decline in liver expression of Abcg2 following several weeks 
of treatment with imatinib. The intestinal expression of Abcb1 and Abcg2 was 
considerably lower than that observed in the liver and it was highly variable, with no 
apparent change in expression with chronic imatinib treatment (data not shown).  
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Figure 1. In vivo change in imatinib concentrations with long-term treatment Black dots and 
bars represent mean (n = 3) and standard error of imatinib concentration in A) plasma and B) 
liver sampled four hours after orally administering mice with 50 mg/kg, following 1, 2, 3 or 4 
weeks of treatment. 
Effect of long-term imatinib treatment in vivo 
117 
Discussion 
The current study demonstrates that, during long-term treatment in mice, imatinib 
is unlikely to induce its own transport or metabolism in vivo, as there was no decrease in 
plasma concentrations of the parent drug. In contrast to the original hypothesis, we found 
that Abcg2 expression actually appears to decline over the treatment period, though no 
significant corresponding increase in plasma or liver concentrations of imatinib was 
observed. The exact mechanism by which imatinib could potentially reduce expression of 
ABCG2 mRNA through activation of a pathway associated with lysosomal degradation 
[16,17]. This and other possible mechanisms are currently under investigation. 
The discordance between the current findings and changes noted both in vitro and 
clinically can be attributed to many factors. It is possible that the upregulation of ABCB1 
and ABCG2 in Caco-2 cells seen by Burger et al. is in fact overestimated, since the 
possibility that chronic imatinib treatment may be essentially selecting for a cell 
population that overexpresses these transporters cannot be entirely excluded. However, 
clinical observations of increased apparent oral clearance over time and reversal of 
resistance with dose escalation suggest that changes in drug metabolism or transport might 
be occurring with long-term treatment. The increased apparent oral clearance could result 
from changes in multiple processes, including decreased drug absorption, increased drug 
metabolism or increased drug excretion.  
Drug disposition in the mouse can vary considerably from that in humans, due to 
physiological differences between the two species. For example, while two CYP3A 
isozymes (including CYP3A4, the major enzyme responsible for imatinib metabolism in 
humans), exist in human intestines and liver, the mouse expresses five different Cyp3a 
isoforms in the intestines, the most predominant of which is Cyp3a13 [18,19]. Based on 
our data, it is likely that similar interspecies differences are affecting long-term 
pharmacokinetics of imatinib and that the mouse may not be a suitable model for 
evaluating these changes in vivo.  
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Figure 2. Change in expression of ABCB1 and ABCG2 during long-term treatment with 
imatinib. Mouse livers were harvested prior to, or following 1, 2 or 3 weeks of treatment with 
50 mg/kg 5x per week, via oral gavage. Liver lysates from two different animals were assessed 
at each weekly time-point, by Western blot analysis.  
 
 
Many studies have examined factors affecting the pharmacokinetic variability of 
imatinib. In humans, polymorphisms in the genes encoding metabolizing enzymes and 
transporter proteins can potentially affect the basal expression and/or functionality, 
thereby resulting in altered drug exposure. An initial study of 9 allelic variants in 82 
patients found no correlation between polymorphisms in ABCB1, ABCG2, CYP2C9, 
CYP2C19 or CYP3A4 and imatinib clearance at steady-state.[20] However, a smaller 
subsequent study found a correlation between ABCB1 polymorphisms and steady-state 
clearance of imatinib [21]. In direct contradiction to the findings of Judson et al., in this 
study, an overall decrease in clearance was observed, from day 1 to steady-state. The most 
significant decreases in clearance were seen in individuals homozygous for the allele with 
the most transport activity (3435CC). Gurney et al. showed that there was no significant 
change in clearance for those individuals that already expressed variant ABCB1 associated 
with low activity, suggesting that imatinib may be actually decreasing the expression of 
ABCB1 or inhibiting its function [21]. 
α1-acid glycoprotein (AAG) has also been purported to play several roles in 
imatinib treatment outcome. In vitro studies have demonstrated that imatinib is 
approximately 95% protein bound in plasma, primarily to AAG and albumin [1]. 
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Clinically, AAG levels are higher in patients with leukemia than in healthy controls, and 
imatinib treatment does not appear to alter expression [22,23]. Le Coutre et al. have 
reported in two studies that patients with elevated AAG responded less rapidly to imatinib 
treatment, but there was no correlation with resistance [23]. In a subsequent clinical study, 
the same authors reported that relapsed patients had significantly elevated AAG as 
compared to responders [24]. While increased AAG may decrease the unbound fraction of 
imatinib, potentially altering both drug exposure and clearance, higher AAG has also been 
correlated with decreased CYP3A4 activity [25]. Indeed, Delbaldo et al. reported a 
correlation between increased AAG levels and decreased imatinib clearance [26].  
In order to conclusively assess the possibility of pharmacokinetic resistance arising 
from modulation of drug disposition via changes in protein binding, metabolism, or 
transport, long-term pharmacokinetic studies must be embarked upon. Assessment of 
steady-state pharmacokinetics at monthly intervals would allow for determination of long-
term changes in drug clearance. Additionally, measurement of the major metabolite of 
imatinib, CGP74588, which is formed by CYP3A4, possibly performed in conjunction 
with phenotyping experiments to determine CYP3A activity, could shed further light on 
potential alterations in metabolism. Furthermore, it would be of interest to measure the 
unbound fraction of imatinib in these serial samples. Direct measurement of unbound 
drug concentrations would allow for a confirmatory assessment of the role of AAG in 
imatinib pharmacokinetics, and would highlight any correlation between the 
pharmacologically active fraction unbound imatinib, that can penetrate tumor cells, and 
the development of resistance to treatment. 
Collectively, the current study suggests that imatinib does not cause upregulation of 
ABC transporters in the hepatic and intestinal compartments in mice. These data do not 
support the possibility that autoinduction contributes to the development of resistance to 
imatinib.  
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Abstract 
Objective: To explore the relationships between imatinib pharmacokinetics and 9 allelic 
variants in 7 genes coding for ATP binding-cassette transporters (ABCB1, ABCG2) and 
enzymes (CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5) of putative relevance for 
imatinib. 
Methods: Imatinib transport in vitro was studied using HEK293 cells transfected with wild-
type ABCG2 and an ABCG2 Q141K clone. Steady-state pharmacokinetics of imatinib 
were obtained in 82 patients with gastrointestinal stromal tumors treated with oral 
imatinib at doses ranging from 100 to 1000 mg/day. Genotyping was carried out using 
direct sequencing or restriction fragment length polymorphism-based techniques. 
Results: HEK293 cells transfected with ABCG2 Q141K exhibited greater drug 
accumulation in vitro than the cells expressing wild-type ABCG2 (P = .028). However, 
pharmacokinetic parameters of imatinib in vivo were not statistically significantly different 
in 16 patients that were heterozygous for ABCG2 421C>A compared to 66 patients 
carrying the wild-type sequence (P = .479). The apparent oral clearance of imatinib was 
reduced in individuals with at least one CYP2D6*4 allele (median, 7.78 versus 10.6 L/h; P 
= .0695). Pharmacokinetic parameters were not related to any of the other multiple-
variant genotypes (P ≥ .230), possibly due to the low allele frequencies. 
Conclusions: This study indicates that common genetic variants in the evaluated genes 
have only a limited impact on the pharmacokinetics of imatinib. Further investigation is 
required to quantitatively assess the clinical significance of homozygous variant ABCG2 
and CYP2D6 genotypes in patients treated with imatinib. 
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Introduction 
Imatinib mesylate (Gleevec, Glivec; hereafter referred to as imatinib), an orally 
administered selective Bcr-Abl and c-kit tyrosine kinase inhibitor, is currently approved for 
the treatment of Philadelphia chromosome-positive chronic myeloid leukemia and KIT 
positive, unresectable and/or metastatic malignant gastrointestinal stromal tumors. The 
degree of interindividual pharmacokinetic variability observed with imatinib is substantial, 
yet remains largely unexplained. For example, Judson et al. recently reported 73% 
variation in the apparent oral clearance of imatinib administered to 42 patients with 
gastrointestinal stromal tumor [1]. They also demonstrated a strong association between 
pharmacokinetic parameters of imatinib and the severity of hematological toxicity (i.e., 
neutropenia and thrombocytopenia) [1]. Similar variability was also seen following 
administration of imatinib to patients with chronic myeloid leukemia [2]. Hence, 
identification of factors affecting the pharmacokinetic profile of imatinib could aid in 
predicting or adapting appropriate, individualized doses of this drug. 
We have recently shown that imatinib is a substrate for ABCG2 [formerly ABC 
transporter in placenta (ABCP), breast cancer resistance protein (BCRP), or mitoxantrone 
resistance protein (MXR)], a highly polymorphic transporter protein that influences the 
absorption and disposition of various substrates [3]. Like ABCB1 (P-glycoprotein), ABCG2 
functions as an efflux transporter, possibly decreasing the amount of substrate drug 
absorbed after oral intake due to its localization on the apical surface of intestinal 
epithelial cells. Furthermore, ABCG2 may increase systemic drug elimination, as it is 
expressed in proximal renal tubular cells and on the biliary surface of hepatocytes [4]. 
Various naturally-occurring variants in ABCG2 are known to affect the function and/or 
expression of its encoded protein. In particular, a functional single-nucleotide 
polymorphism (SNP) has been identified in exon 5 of the ABCG2 gene, in which a C>A 
nucleotide transition at position 421 (ABCG2 421C>A) results in a non-synonymous 
variant protein with a glutamine to lysine amino acid substitution at codon 141 (Q141K) 
[5]. The purpose of the present study was to investigate the association between the 
ABCG2 421C>A polymorphism and the pharmacokinetics of imatinib in a cohort of 
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patients with gastrointestinal stromal tumors. Since in vitro studies have shown that 
imatinib is transported by ABCB1[6] and extensively metabolized by the cytochrome P450 
isoforms CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 [7], we also analyzed 
common genetic polymorphisms in the genes encoding these proteins, in order to provide 
a stronger scientific basis for optimizing imatinib therapy on the basis of each patient’s 
genetic constitution. 
 
Methods 
In vitro cellular accumulation 
Human embryonic kidney cells (HEK293) cells transfected with pcDNA3, wild-type 
ABCG2, or an ABCG2 Q141K clone were generated as described previously [8]. Cells 
were maintained in HEPES-buffered RPMI 1640 supplemented with 10% (v/v) fetal calf 
serum. 14C-labeled imatinib was provided by Novartis (Basel, Switzerland). 
Preliminary experiments indicated that the relative accumulation between ABCG2-
overexpressing cells and the parental cells independent of the concentration in the range 
of 0.02 to 2.0 µM. In the experiments presented here, HEK293 cells (106/mL) were 
exposed to 14C-labeled imatinib at a total drug concentration of 0.64 µM (corresponding to 
0.03 µCi of radioactivity) for 2 hours at 37°C, and then washed three times with ice-cold 
phosphate-buffered saline. Accumulation of imatinib was calculated from the radioactivity 
measured in the cell pellet over that retained in the supernatant, as determined by liquid 
scintillation counting. The ABCG2 protein level was determined in the HEK293 cells by 
Western blot analysis using the monoclonal BXP-21 antibody (1:200 dilution), kindly 
provided by Dr. George L. Scheffer (Vrije Universiteit Medical Center, Amsterdam, The 
Netherlands). A mouse monoclonal anti-β-actin (1:5,000) was used to confirm equal 
loading, as described previously [9]. Since ABCG2 is a homo-oligomeric protein, total 
protein lysates were isolated in the presence of β-mercaptoethanol and sodium dodecyl 
sulfate, and boiled for 5 minutes prior to gel electrophoresis and detection of only the 
monomeric form of the ABCG2 protein. 
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Patient treatment 
Patients with histological evidence of soft tissue sarcoma, including gastrointestinal 
stromal tumors (c-kit positivity before entry was required), were considered eligible for this 
study. Additional eligibility criteria for participation included: a) a measurable lesion with 
evidence of progression within 6 weeks prior to treatment (osseous lesions and pleural 
effusions are not considered measurable); b) no radiotherapy or embolization to the sole 
index lesion; c) age ≥15 years; d) World Health Organization performance status of < 2; e) 
adequate hematopoietic function (absolute neutrophil count, ≥ 1.5 × 109/1iter and platelet 
count, ≥ 100 × 109/L); and f) adequate renal function (serum creatinine, £ 120 mmol/L or 
calculated clearance (Cockroft method), > 65 mL/min) and hepatic function (bilirubin, 
£ 30 mmol/L; serum albumin, > 25 g/L). Specific exclusion criteria included: a) other 
severe medical illness, including psychosis and previous history of cardiovascular disease; 
b) concurrent treatment with warfarin; c) symptomatic or known central nervous system 
metastases; d) prior or concurrent second primary malignant tumors (except adequately 
treated in situ carcinoma of the cervix, or basal cell carcinoma); e) women of child-
bearing potential unless in case of adequate contraceptive measures; and f) patients for 
whom regular follow-up attendance are impractical. None of the patients receive any 
medication aside from imatinib that could possibly influence the activity of ABCG2 or the 
pharmacokinetic profile of imatinib. The study protocol was approved by the Institutional 
Review Boards (Leuven, Belgium; and Rotterdam, the Netherlands), and before patient 
registration, written informed consent was obtained from each patient according to 
ICH/EU GCP and national/local regulations. Toxicity and efficacy data were not 
considered as pharmacodynamic endpoints in the current study due to the fact that 
different dosing schedules were used in the studied population. 
 
Blood sampling 
Blood sampling was performed on each patient after steady-state plasma 
concentrations had been achieved (at approximately 28 days after the start of drug 
administration). At this time, serial blood samples (8 mL each) were drawn immediately 
before drug administration and at 1, 2, 3, 4, 6, and 24 hours after drug intake, in order to 
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provide a full pharmacokinetic profile over one dosing interval. In 12 patients, additional 
samples were obtained at 30 minutes and at 5, 8, 10, and 18 hours after drug intake.  All 
blood samples were collected in glass tubes containing heparin. Patency of the catheter 
between blood draws was maintained with a heparin lock (10 U/mL in normal saline) or 
slow normal saline drip (10 mL/h). Immediately after collection, blood samples were 
centrifuged at 4000 g for 15 minutes, and the plasma was separated and stored in 
polypropylene vials at –20°C until analysis. 
 
Analytical measurements 
Imatinib concentrations in plasma were determined by validated analytical 
methods using liquid chromatography with ultraviolet or tandem mass-spectrometric 
detection [10]. Briefly, imatinib and the internal standard [2H8]imatinib were extracted 
with a single protein precipitation step by the addition of acetonitrile to and plasma. The 
analytes of interest were then separated on a Waters Symmetry C18 column (50 × 2.1 mm 
internal diameter; 3.5 µm particle size) using a mobile phase composed of a mixture of 
methanol-0.05% ammonium acetate (72:28, v/v). Imatinib and the internal standard were 
detected by electrospray tandem mass spectrometry (Micromass Quattro Ultima triple 
quadrupole mass spectrometer; Micromass, Manchester, UK) in the positive mode, and 
monitored in the multiple reaction monitoring transitions 494>394 and 502>394, 
respectively. The linearity and reproducibility of the imatinib calibration curves in human 
plasma were satisfactory between 1 and 10,000 ng/mL, and the lower limit of quantitation 
was 1 ng/mL. The mean intraday accuracies at the lower limit of quantitation for imatinib 
were between 99.8 and 102%, with values for the relative standard deviation between 
5.74% and 2.39%. Above the lower limit of quantitation, the mean intra-day accuracies 
ranged from 99.8 to 102%. 
 
Pharmacokinetic analysis 
Pharmacokinetic profiles were evaluated by non-compartmental analysis using the 
software package WinNonlin version 5.0 (Pharsight, Mountain View, Calif), and the 
parameters of interest included the area under the curve for one dosing interval (AUC0-24), 
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the apparent oral clearance (CL/F), and the average steady-state plasma concentration (Css). 
Previously, it was shown that imatinib exposure is dose-proportional for the dose range of 
25 to 1,000 mg [2], indicating linear pharmacokinetics. Therefore, AUC0-24 and Css 
estimates were dose-normalized to account for the different dosages administered. 
 
Genotype analysis 
Genomic deoxyribonucleic acid (DNA) was isolated from plasma using the 
UltraSens Virus Kit (Qiagen, Valencia, Calif).  The CYP2C9 430C>T (CYP2C9*2), CYP2C9 
1075A>C (CYP2C9*3), CYP2C19 681G>A (CYP2C19*2), CYP2C19 636G>A (CYP2C19*3), 
CYP2D6 1846G>A (CYP2D6*4), CYP3A4 -392A>G (CYP3A4*1B), CYP3A5 6986A>G 
(CYP3A5*3C), ABCB1 3435C>T, and ABCG2 421C>A variants were analyzed by 
polymerase chain reaction (PCR)-restriction fragment length polymorphism-based 
techniques, as described previously [11-13]. The selection of these particular polymorphic 
variants in our predominantly Caucasian population was based on considerations 
provided elsewhere [14]. Confirmation of variant ABCG2 genotype assignments was 
performed using direct nucleotide sequencing, following nested PCR.  An initial PCR was 
performed with concentrated DNA utilizing 20 pmol of each primer. Primers were 
designed as follows:  5’-CTATTTGGGTGTACAGATAGGGG-3’ and 5’-
CACGTTCATATTATGTAACAAGCC-3’. These primers were added to a reaction mixture of 
1× PCR buffer, 2 mM of each of the four deoxynucleotide triphosphates (dNTPs), 1.5 mM 
MgCl2, and 2 units of Platinum Taq polymerase (Invitrogen, Carlsbad, Calif) in a reaction 
volume of 20 µL. The temperature profile for the first reaction was: 5 minutes at 94oC, 20 
cycles (30 seconds at 94 oC, 30 seconds at 63oC, 30 seconds at 72oC), then 7 minutes at 
72oC. After initial amplification, 3 µL of amplified product was removed and an additional 
PCR amplification was performed using 40 pmol of the primers 5’-
GCAGGTTCATCATTAGCTAGAAC-3’ and 5’-CCTACTTATGCTGATCATGAGC-3’ in a 50-
µL reaction. Secondary PCR was carried out at the same temperatures, using 40 cycles. 
Direct nucleotide sequencing was performed using the following primers: 5’-
CTTAAGGATGATGTTGTGATGGG-3’ for the forward strand, and 5’-
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TCTTGAATGACCCTGTTAATCCG-3’ for the reverse strand with dRhodamine Terminator 
Cycle Sequencing Ready Reaction kit on an ABI 310 genetic analyzer (Applied Biosystems, 
Foster City, Calif). The genotype was called variant if it differed from the Refseq consensus 
sequence for the SNP position (http://www.ncbi.nlm.nih.gov/LocusLink/refseq.html). 
Genotype-frequency analysis of Hardy-Weinberg equilibrium was carried out using 
Clump version 1.9. 
 
Statistical analysis 
All data are presented as median values with 95% confidence intervals (95%CI), 
unless indicated otherwise. Differences in intracellular imatinib accumulation in the cell 
lines as well as the differences in pharmacokinetic parameters of imatinib as a function of 
drug dose, sex, and the different genotypes were evaluated using a non-parametric 
Kruskal-Wallis one-way analysis of variance on ranks.  The relationship between patient 
age and the apparent oral clearance of imatinib was assessed using Spearman rank 
correlation analysis. In case of two dichotomous variables, a Fisher’s exact test was 
performed. Because this study was mainly exploratory in intent, no adjustments were 
performed to evaluate the significance of the multiple comparisons. Two-tailed P values of 
less than .05 were considered to be statistically significant. All statistical calculations were 
performed in the software package NCSS version 2001 (Number Cruncher Statistical 
System; J. Hintze, Kaysville, Utah). 
 
Results 
In vitro transport of imatinib by ABCG2 
In order to investigate the potential effect of the ABCG2 421C>A variant on the 
protein’s ability to transport imatinib, human embryonic kidney cells (HEK293) cells 
transfected with pcDNA3, wild-type ABCG2, or an ABCG2 Q141K clone were exposed to 
14C-labeled imatinib for 2 hours and the intracellular concentration determined. The 
overexpression of wild-type ABCG2 resulted in significant decrease in drug accumulation 
compared to cells lacking ABCG2 (P < .01), confirming that imatinib is a substrate for the 
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wild-type ABCG2 protein (Fig 1). The cells homozygous for the studied variant exhibited 
significantly greater drug accumulation than the cells expressing wild-type ABCG2 (P 
= .028), suggesting impaired outward-directed transport of imatinib by the ABCG2 Q141K 
variant (Fig 1). Following this in vitro observation, we sought to determine whether 
patients carrying this genetic variant would have increased exposure to imatinib. 
 
 
Fig 1. Comparative intracellular accumulation of 14C-labeled imatinib ([14C]imatinib) in human 
embryonic kidney cells (HEK293) transfected with wild-type ABCG2 (HEK293/R), and an ABCG2 
Q141K clone (HEK293/K-5). Data are expressed as mean (bars) ± standard deviation (error bars) of 
two experiments each carried out in at least duplicate as the percent accumulation observed 
relative to that in HEK293 cells transfected with (empty vector) pcDNA3 (HEK293/Neo). The 
HEK293/Neo, HEK293/R, and HEK293/K-5 cells showed normalized intracellular accumulation 
values of 100 ± 5%, 55 ± 4%, and 84 ± 9%, respectively. The star (*) indicates statistically 
significant differences (P < .05) in the intracellular accumulation of 14C-labeled imatinib between 
the tested cell lines. The bottom panel shows a comparative Western blot analysis for ABCG2 in 
the 3 cell lines to demonstrate the similarity in protein expression levels between the HEK293/R 
and HEK293/K-5 cells and the absence of ABCG2 expression in the HEK293/Neo cells [9]. 
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Patients and imatinib pharmacokinetics 
Eighty-two patients with cancer (80 patients with gastrointestinal stromal tumors 
and two patients with dermatofibrosarcoma protuberans), were treated with oral imatinib, 
given daily at a dose ranging from 100 to 1000 mg (median dose, 400 mg). The cohort 
consisted of 79 Caucasians, and 3 patients of Asian ancestry. In total, there were 53 males 
and 29 females, and the median age was 58 years (range, 25 to 80 years). The individual 
and average pharmacokinetic parameters of imatinib at steady-state are consistent with 
previous findings from patients on a similar regimen [7]. The apparent oral clearance was 
not statistically significantly dependent on drug dose (P = .299), consistent with a linear 
pharmacokinetic profile, as suggested previously [2]. Interindividual pharmacokinetic 
variability of imatinib was extensive, and the apparent oral clearance ranged more than 
60-fold, from 0.86 to 62 L/h, in the studied population. The clearance histogram indicated 
a leptokurtic unimodal distribution with skewness to the right, with an overall median 
value of 9.14 L/h (95%CI, 7.78 to 10.7 L/h) and a coefficient of variation of 91.6% (Fig 2). 
To exclude the possibility of sex-related differences in the individuals evaluated in the 
present analysis, pharmacokinetic parameters were also compared between the groups. 
The apparent oral clearance was slightly higher in males (median, 8.47 L/h; 95% CI, 6.31 
to 9.75 L/h) as compared to females (median, 7.80 L/h; 95% CI, 5.81 to 11.8 L/h), but this 
difference was not statistically significant (P = .163). Likewise, the apparent oral clearance 
of imatinib was unrelated to age (Spearman rank = -0.0420; P = .710). 
 
Variant Genotypes 
Of the 82 patients included in this analysis, 66 patients had two wild-type alleles 
(wild-type genotype) and 16 patients had inherited one copy of the variant ABCG2 
421C>A allele (heterozygous variant genotype), resulting in an allele frequency of 0.0976, 
which is consistent with previous findings for a predominantly Caucasian population [15]. 
No patients homozygous for this variant allele were identified.  Eight additional SNPs were 
analyzed in 6 genes of putative relevance for imatinib absorption and disposition. In one 
of the tested SNPs (i.e., CYP2C19*3), no variants were observed. In the other 
polymorphisms studied, frequencies of the rarest alleles ranged from 0.0429 to 0.494 
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(Table I). All genotype frequencies were found to be in Hardy-Weinberg equilibrium, and 
complete genetic linkage was not seen among polymorphisms from within the same gene. 
The genotype and allele frequencies are in excellent concordance with previously 
published values for a predominantly Caucasian population [14]. 
 
 
 
 
 
Fig 2. Histogram of the apparent oral clearance of imatinib (CL/F) determined at steady-
state in a cohort of 82 patients with gastrointestinal stromal tumors. 
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Genotype-phenotype associations 
Since the mechanistic basis for associations of the studied genetic variants would 
primarily be with (oral) clearance, we focused on presenting these results. For the 8 
polymorphisms in 6 genes in which variant alleles were observed, none was associated 
with statistically significant differences in the oral clearance of imatinib (Table II and Fig 
3). In contrast to what was predicted based on the in vitro data, the apparent oral 
clearance of imatinib was similar in 16 patients that were heterozygous for ABCG2 
421C>A as compared to 66 patients with the wild-type sequence (P = .479). The apparent 
oral clearance of imatinib was reduced in carriers of at least one CYP2D6*4 allele (median, 
7.78 L/h; 95%CI, 6.17 to 9.75 L/h) compared to individuals carrying two wild-type alleles 
(median, 10.6 L/h; 95%CI, 8.57 to 14.9 L/h). This difference was not statistically 
significant (P = .0695), presumably as a result of the relatively small sample size and the 
presence of only one patient who carried two variant alleles. However, the proportion of 
individuals with an oral clearance of imatinib higher than the median value was 
significantly greater in the group with the reference CYP2D6 sequence (15 of 42 patients; 
35.7%) as compared to the group with at least one CYP2D6*4 allele (3 of 25 patients; 
12.0%; P = .0466). Differences in other pharmacokinetic parameters, including AUC, 
steady-state concentration, and peak concentration, were not statistically significantly 
different between the different genotype groups (data not shown). 
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Fig 3. Individual apparent oral clearance values of imatinib as a function of variant genotypes. 
Wt, wild-type patient; Het, heterozygous variant type patient; Var, homozygous variant type 
patient.  Each symbol represents an individual patient, and horizontal lines represent median 
values within each group. 
 
 
 
Discussion 
The present study suggests that patients carrying one defective ABCG2 421C>A 
allele do not have elevated plasma concentrations of the anticancer agent and ABCG2 
substrate imatinib as compared to those patients with two wild-type alleles. The studied 
variant in ABCG2 is a SNP causing a non-synonymous change in the protein sequence, in 
which a 421C to A transition in exon 5 leads to a glutamine to lysine amino acid 
substitution at codon 141 (Q141K). In contrast to the current clinical observations with 
imatinib, the ABCG2 421C>A allele has been shown previously to be associated with 
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altered pharmacokinetics of the topoisomerase I inhibitors diflomotecan [16], topotecan 
[9], and the irinotecan metabolite, SN-38 [17]. 
The underlying mechanistic reasons for the lack of a significant association 
between the ABCG2 421C>A polymorphism and the observed pharmacokinetic outcome 
in this study are not entirely clear. Although our own current in vitro transport studies in 
HEK293 cells transfected with the homozygous Q141K variant show an increased 
intracellular accumulation of imatinib, it is unclear whether this also holds true for the 
heterozygous situation as seen in the patients. It is also unknown whether ABCG2 is 
(equally) transcribed from both alleles. Furthermore, the functional ABCG2 transporter is a 
homo-oligomeric protein, and hence, in the heterozygous situation, various multimers 
with differing transport capacities may be formed. It is noteworthy that a recent preclinical 
investigation provided evidence that the mouse orthologue Abcg2 significantly affects the 
systemic clearance of imatinib [18]. Collectively, it logically follows that patients with a 
rare genotype comprising two variant alleles at the ABCG2 421C>A locus may show 
markedly impaired ability to eliminate imatinib and subsequently demonstrate excessive 
toxicity. Clearly, additional investigation is required to unambiguously assess the 
relationship between the homozygous variant ABCG2 421C>A genotype and imatinib 
pharmacokinetics. 
Houghton et al. have demonstrated previously that the accumulation and efflux of 
imatinib were not altered between ABCG2-expressing and non-expressing cells with drug 
concentrations higher than those used in the current experiments [19]. Although the 
discrepancies with our data are likely due to methodological issues, such as substantial 
dissimilarities in incubation time and temperature, it is also possible that this phenomenon is 
related in part to saturation or concentration-dependent inhibition of ABCG2 by imatinib, 
which can occur at pharmacologically relevant concentrations of the drug that are 
achieved in patient plasma [19]. Hence, there is the potential for imatinib to modulate its 
own absorption and transporter-mediated elimination regardless of ABCG2 genotype 
status, as suggested previously [20]. Finally, it should be noted that, due to the rapid 
expansion of SNP discovery and the present lack of overlap amongst the various SNP 
databases[21], it cannot be entirely excluded that further functional polymorphisms in this 
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and other genes are still to be described. For example, recent data also suggest that 
molecular determinants of imatinib pharmacokinetics and response might include the 
organic cation transporter SLC22A1 (OCT1) [20], which is encoded by a gene that has 
various common allelic variants [22,23]. Incorporation of this knowledge may eventually 
provide further refinement of the predictive strategies for imatinib. 
A sexual dimorphism in Abcg2 expression in mice and ABCG2 expression in 
humans has recently been demonstrated, with males having higher mRNA levels in the 
liver, but not in the small intestine or kidney [24]. This was shown to result in lower 
plasma concentrations of a variety of ABCG2 substrates, including the antibiotic 
nitrofurantoin, the antiulcerative drug cimetidine, the anticancer agent topotecan, and the 
dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, in male mice 
compared with female mice after both oral and intravenous drug administration [24]. 
Consistent with these observations, the apparent oral clearance of imatinib has also been 
previously shown to exhibit significant sexual dimorphism, being on average 14.5 L/h 
[percent coefficient of variation (%CV), 67%] for males and 7.32 L/h (%CV, 40%) for 
females [1]. Similar sex-dependent differences were also observed in the currently studied 
cohort, even though these values did not reach statistical significance. Hence, the clinical 
importance of this sex effect and the role of ABCG2 in the context of treatment outcome 
with imatinib-containing regimens remain to be established. 
It is of interest to note that the interindividual pharmacokinetic variability for imatinib 
as observed in this study was very substantial, apparently regardless of ABCG2 421C>A 
genotype status, and in spite of earlier reports indicating that the oral bioavailability of 
imatinib in healthy volunteers is approximately 98% [25]. The reasons for this extensive 
pharmacokinetic variability in cancer patients are not yet fully understood, but can likely 
be attributed to intersubject variations in the activity of other transporters and enzymes of 
putative relevance to the pharmacokinetic profile of imatinib. As mentioned previously, 
these include the ATP binding cassette transporters ABCG2 and ABCB1[6], and the 
cytochrome P450 isoforms CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5, [26]. 
Prior in vitro studies have shown that CYP3A4 is the major enzyme involved in the 
biotransformation of imatinib, and that the apparent oral clearance of imatinib is sensitive 
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to concurrent administration of typical inhibitors of this enzyme such as ketoconazole[27] 
as well as inducers such as rifampin [28] and St. John’s wort [29]. Variability in CYP3A4 
activity between cancer patients has been shown to be particularly large [30,31] and this 
may therefore, in part, contribute to the large intersubject variability in imatinib 
pharmacokinetic parameters observed here. 
Previous work has shown that certain variants in the ABCB1 gene are associated 
with reduced expression of its encoded protein [32], and that this may result in decreased 
intestinal and hepatobiliary secretion of substrate drugs. In this study, imatinib 
pharmacokinetics were not statistically significantly influenced by the common ABCB1 
3435C>T allele. This observation is in line with the notion that the effect of ABCB1 
genotype is a relatively unimportant contributing factor to the pharmacokinetics of 
substrate drugs unless ABCB1-mediated transport is the crucial process in oral absorption 
[4]. The lack of effect of the evaluated variants in the CYP3A4 and CYP3A5 genes on 
imatinib pharmacokinetics is also consistent with the relatively low allelic frequencies in 
the Caucasian population and the available functional data indicating a limited role of 
such variants in the interindividual variability of CYP3A expression and activity in patients 
with cancer [31]. The lack of functional significance of the studied CYP2C9 and CYP2C19 
variants in relation to imatinib pharmacokinetics is likely the result of the small relative 
contribution of these two isoforms to overall drug elimination [7]. 
One intriguing observation in the current study was that the median apparent oral 
clearance of imatinib was reduced in carriers of at least one CYP2D6*4 allele, reaching 
borderline significance. Furthermore, patients with an oral clearance of imatinib higher 
than the median value were more likely to carry two copies of the reference CYP2D6 
sequence. Previous investigation has demonstrated that imatinib is excreted 
predominantly via the biliary-fecal route, but with only up to 28% of the dose in the 
excreta corresponding to parent drug. Since imatinib is a known potent inhibitor of 
CYP3A4 [33], it is theoretically plausible that, at steady-state, imatinib inhibits its own 
primary oxidation pathway and that metabolism is shunted to CYP2D6-mediated routes. 
In this scenario, the non-functional CYP2D6*4 allele becomes of central interest as it is 
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carried by approximately 75% of CYP2D6 poor metabolizers in the Caucasian population 
[34]. 
In view of the presence of only one patient with homozygosity for this CYP2D6 
allele in our population as well as the relatively small sample size studied here, 
independent confirmation is needed to corroborate our findings. However, the magnitude 
of the observed effect of the CYP2D6*4 genotype suggests that the overall impact might be 
of clinical importance with respect to pharmacodynamic outcome following treatment 
with imatinib. In this context, it is noteworthy that various studies have shown marked 
differences in genotype and allele frequencies for CYP2D6 variants between different 
ethnic populations. Although the CYP2D6*4 allele is rarely found in Asians [35], other 
alleles associated with low substrate affinity and low activity can play an important role in 
drug metabolism in this population. For example, the CYP2D6*10 allele may be present in 
as much as 50% of Asians and is responsible for diminished enzyme activity and this may 
have therapeutic and prognostic implications [35]. This possibility is further exemplified 
by the observation that Asians have increased susceptibility to imatinib-induced 
hematological toxicity compared to Caucasians at the currently recommended drug doses 
[36]. For examples, there has been concern that dosing of imatinib at a dose of 400 mg, 
the recommended daily dose in the United States, may be too high for Japanese patients, 
based on the high incidence and severity of drug-induced thrombocytopenia in this 
population [37]. Additional analysis in patients of diverse ethnic background is clearly 
required to further resolve this issue. 
In conclusion, this study indicates that the presently evaluated variant alleles in the 
CYP2C9, CYP2C19, CYP3A4, CYP3A5, ABCB1 and ABCG2 genes do not contribute 
substantially to explaining the extensive interindividual variability in imatinib 
pharmacokinetics. It is possible that additional genetic variants or haplotypes of 
importance to imatinib pharmacokinetics may yet be discovered. Further investigation, 
particularly with respect to homozygosity of variants in the ABCG2 and CYP2D6 genes, is 
needed to determine the relative role of genetic variation and environmental variables on 
the absorption and disposition of imatinib. 
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Imatinib mesylate, the first tyrosine kinase inhibitor to gain approval by the FDA, 
remains as a pivotal example of rational drug design. Initially, imatinib was found to target 
the bcr-abl fusion protein in CML and further targets have subsequently been identified, 
including c-kit in GIST.  Though a great number of studies have elucidated underlying 
mechanisms to explain emerging resistance to this anti-cancer agent, many cases of 
resistance remain unexplained. Furthermore, patients exhibit high interindividual 
variability in imatinib pharmacokinetics, which may contribute to suboptimal drug 
exposure and response.  
Chapter 2 provides a literature review on the role of two ABC transporter proteins, 
ABCB1 (P-glycoprotein) and ABCG2 (BCRP), both of which are expressed ubiquitously 
throughout the body and have been shown to transport imatinib. 
Cytochrome P450 3A4  (CYP3A4) is considered to be the major enzyme involved 
in metabolism of imatinib. Midazolam, a benzodiazepine sedative, can be used as a probe 
to assess CYP3A4 and CYP3A5 activity in vivo. Chapter 3 details the development and 
validation of a novel, sensitive assay employing LC-MS technology for the measurement of 
midazolam in human plasma. In Chapter 4, this assay was utilized to evaluate the 
pharmacokinetics of midazolam in a group of individuals with cancer, for assessment of 
CYP3A4 and CYP3A5 activity. The midazolam pharmacokinetic parameters were then 
correlated with polymorphisms in the CYP3A4, CYP3A5 and ABCB1 genes, to determine 
whether these mutations can account for the interindividual variability observed. In this 
population of 58 patients, no statistically significant correlations were found between any 
of the six polymorphisms and midazolam drug exposure (AUC), volume of distribution or 
drug clearance. As such, the highly variable activity of CYP3A4 and CYP3A5 does not 
appear to be directly due to genetic differences in the genes encoding them.  
In Chapter 5, the effect of tariquidar, a dual inhibitor of both ABCB1 and ABCG2, 
on the pharmacokinetics of imatinib was evaluated in vivo. It was hypothesized that the 
addition of a transport inhibitor would increase drug concentrations in both plasma and 
tissues. It was of particular interest to determine whether increased penetration into the 
brain could be achieved. Oral administration of tariquidar, 30 minutes prior to imatinib 
administration, more than doubled exposure to imatinib in plasma. As anticipated, there 
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was no apparent change in the rate or extent of drug absorption, presumably due to the 
high bioavailability of imatinib. Though the brain exposure to imatinib also increased over 
110% with tariquidar pretreatment, the overall brain-to-plasma ratio did not differ 
between the two groups. Presumably, tariquidar is inhibiting ABCB1 and ABCG2 
expression in the liver and kidneys, leading to decreased drug elimination. Overall, these 
findings suggest that significant modulation of the blood brain barrier is not occurring with 
tariquidar. It is also possible that if used in a clinical setting, the increased plasma drug 
exposure may also increase the severity or frequency of side effects.  
Clinical observations of increased imatinib clearance with long-term treatment 
brought forth the idea that the drug may be inducing its own elimination, through 
upregulation of transporter proteins or metabolizing enzymes. As increases in drug 
clearance could result in suboptimal drug exposure, this phenomenon may result in the 
development of pharmacokinetic resistance. Indeed, dose escalation has been shown to 
overcome resistance. Chapter 6 details the effects of long-term treatment of normal mice 
with daily imatinib.  Plasma concentrations of imatinib and expression of Abcb1 and 
Abcg2 were evaluated each week for four weeks. Plasma and liver concentrations of 
imatinib did not change significantly over the course of treatment. In contrast to in vitro 
findings published by Burger et al., there was no apparent increase in Abcb1 or Abcg2 
expression in liver or intestinal samples. As such, the mouse does not appear to develop 
pharmacokinetic resistance to imatinib as noted in humans and cannot be used to 
elucidate the causes of this resistance. 
Finally, in Chapter 7, nine single nucleotide polymorphisms in seven genes 
involved in imatinib metabolism or transport were assessed in 82 patients treated with 
imatinib for gastrointestinal stromal tumors. In vitro, we demonstrated that the Q141K 
polymorpshim in ABCG2 results in significantly higher intracellular accumulation of 
imatinib. However, this finding was not confirmed in vivo. No significant correlations 
were found between polymorphisms in ABCB1, ABCG2, CYP2C9, CYP2C19, CYP2D6, 
CYP3A4 or CYP3A5 and the apparent oral clearance of imatinib.  
The work presented in this thesis aimed to identify factors involved in the 
interindividual pharmacokinetic variability and development of pharmacokinetic 
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resistance to treatment with imatinib. Though CYP3A4 is the major enzyme responsible 
for metabolism of imatinib, polymorphisms in this gene did not correlate with steady-state 
pharmacokinetic parameters. Furthermore, it was demonstrated that polymorphisms in 
CYP3A4 and CYP3A5 are not surrogates for activity of the encoded enzymes in patients 
with cancer, as assessed using midazolam as a probe substrate.  
Based on previous publications and our own in vitro findings, ABCG2 was 
hypothesized to play a major role in imatinib disposition, potentially increasing drug 
exposure for those with one or more Q141K alleles and/or leading to the increased drug 
clearance over time if imatinib was inducing ABCG2. However, pre-clinical and 
retrospective clinical studies did not confirm the in vitro results.   
It is likely that the interindividual pharmacokinetic variability of imatinib cannot be 
attributed to a single transporter or enzyme, but that many factors in the disposition of this 
agent must be considered in combination. Furthermore, it appears that the mouse is not a 
suitable model for studying the development of pharmacokinetic resistance. A long-term, 
prospective clinical study of imatinib may offer considerable insight. Ideally, a study of 
this type would involve measurement of imatinib steady-state pharmacokinetics at 
monthly intervals. In addition, analysis of CGP74588, the major metabolite of imatinib 
formed by CYP3A4, coupled with repeated midazolam phenotyping to assess activity, 
would hopefully elucidate the role of this enzyme in variability, as well as changes over 
time. Along with pharmacogenetics, all of the data collected could be incorporated into a 
population pharmacokinetic model, allowing for assessment of many covariates which 
may be contributing to interindividual variability or long-term changes in drug clearance. 
It is only once the contributing factors are elucidated that successful mechanisms for 
overcoming these barriers to safe, yet highly effective treatment with imatinib can be 
explored.  
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Imatinib mesylaat was de eerste tyrosinekinaseremmer die door de Amerikaanse 
‘Food and Drug Administration’ (FDA) werd toegelaten tot de markt.  Dit middel wordt 
thans beschouwd als een schoolvoorbeeld van de rationele geneesmiddelontwikkeling.  
Alhoewel aanvankelijk werd verondersteld dat het werkingsmechanisme van imatinib 
louter was gebaseerd op een interactie met het zogenaamde Bcr-Abl eiwit in chronische 
myeloïde leukemie (CML) zijn er later additionele aangrijpingspunten ontdekt, waaronder 
het c-KIT eiwit in gastrointestinale stromatumoren (GIST).  Veel onderzoek is recent 
verricht naar de mechanismen die ten grondslag liggen aan het optreden van resistentie 
tegen imatinib.  Echter, in vele gevallen blijft de exacte oorzaak voor het optreden van 
deze resistentie onopgehelderd.  Eerder onderzoek heeft uitgewezen dat het 
farmacokinetisch gedrag van imatinib tussen patiënten onderling zeer sterk varieert, en het 
is mogelijk dat deze mate van variabiliteit bijdraagt aan een te lage blootstelling aan het 
middel, met als gevolg een verminderde kans op een respons. 
In hoofdstuk 2 wordt een literatuuroverzicht gegeven van recente ontwikkelingen 
in een aantal factoren die van invloed kunnen zijn op de farmacokinetiek van imatinib.  In 
het bijzonder wordt aandacht geschonken aan twee transporteiwitten, met name ABCB1 
(P-glycoproteïne) en ABCG2 (BCRP), en hun specifieke rol in de absorptie en eliminatie 
van diverse antikankergeneesmiddelen. 
Over het algemeen wordt verondersteld dat het enzyme cytochrome P450 3A4 
(CYP3A4) het belangrijkste metaboliserende eiwit is dat de eliminatie van imatinib 
reguleert.  De fenotypische activiteit van dit CYP3A4 kan vastgesteld worden aan de hand 
van een test waarbij het benzodiazepinederivaat midazolam aan patiënten wordt 
toegediend.  In hoofdstuk 3 wordt de ontwikkeling en validatie beschreven van een 
analytische methode voor het bepalen van midazolamconcentraties in humaan 
bloedplasma, gebruikmakend van hogedruk-vloeistof chromatografie met 
massaspectrometrische (LC-MS) detectie.  Deze methodiek werd vervolgens toegepast in 
het onderzoek beschreven in hoofdstuk 4, waarin de activiteit van CYP3A4 en het 
gerelateerde enzyme CYP3A5 is onderzocht in 58 kankerpatiënten.  De farmacokinetische 
parameters voor midazolam werden vervolgens gecorreleerd aan een zestal 
polymorfismen in de CYP3A4, CYP3A5 en ABCB1 genen om vast te stellen of genetische 
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mutaties een bijdrage leveren aan de gevonden interindividuele variabiliteit in de klaring 
van midazolam.  In de onderzochte populatie werden geen statistisch significante relaties 
gevonden tussen de 6 polymorfismen en de blootstelling aan midazolam (AUC), het 
distributievolume of de klaring.  Derhalve kon worden geconcludeerd dat interindividuele 
variabiliteit in de activiteit van CYP3A4, CYP3A5 en ABCB1 waarschijnlijk niet in 
belangrijke mate wordt bepaald door genetische verschillen tussen patiënten in de genen 
die deze eiwitten tot expressie brengen. 
In hoofdstuk 5 is de invloed onderzocht van tariquidar, een remmer van de ABCB1 
en ABCG2 transporteiwitten, op de farmacokinetiek van imatinib in een proefdiermodel.  
Dit onderzoek was gebaseerd op de hypothese dat behandeling met een dergelijke middel 
zal resulteren in verhoogde concentraties van imatinib in bloedplasma en weefsels, in het 
bijzonder de hersenen.  Er werd gevonden dat tariquidar, wanneer oraal toegediend 30 
minuten voorafgaand aan imatinib, de systemische blootstelling aan imatinib meer dan 
verdubbelde.  Tariquidar had geen invloed op de snelheid en mate van de 
gastrointestinale absorptie van imatinib, hetgeen in overeenstemming is met de eerder 
beschreven hoge orale biologische beschikbaarheid van dit middel.  Alhoewel de 
blootstelling aan imatinib in hersenweefsel met meer dan 110% toenam in aanwezigheid 
van tariquidar, werd geen verschil gevonden in de concentratieratio voor hersenen en 
plasma in de aan- of afwezigheid van tariquidar.  Deze bevindingen zijn consistent met de 
gedachte dat tariquidar de functie van ABCB1 en ABCG2 efficient kan remmen in de lever 
maar niet in de hersenen.  Dit proces heeft tot gevolg een vertraagde eliminatie van 
imatinib zonder dat de functie van de bloed-hersenbarriere wordt beïnvloed.  Het ligt voor 
de hand dat, indien dit concept zou toegepast worden in de kliniek, de verhoogde 
bloedplasmaconcentraties van imatinib in aanwezigheid van tariquidar zullen resulteren 
in een toename in de mate en ernst van ongewenste bijwerkingen. 
Eerder klinisch onderzoek heeft uitgewezen dat langdurige behandeling met 
imatinib kan leiden tot een verhoogde klaring van dit middel.  Deze bevinding is mogelijk 
het gevolg van autoinductie, een proces waarbij een geneesmiddel zijn eigen eliminatie 
kan versnellen door het induceren van de expressie van enzymen en transporteiwitten.  
Aangezien een verhoogde klaring kan leiden tot suboptimale blootstelling aan een middel 
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kan dit proces uiteindelijk resulteren in de ontwikkeling van zogenaamde 
farmacokinetische resistentie, waarbij patiënten een hogere dosis imatinib behoeven om 
de beoogde therapeutische effecten te verkrijgen.  In hoofdstuk 6 is de invloed onderzocht 
van langdurige blootstelling aan imatinib, na dagelijkse toediening aan muizen, op de 
expressie van Abcb1 en Abcg2.  Gedurende een behandelperiode van 4 weken werd 
gevonden dat de concentraties van imatinib in bloedplasma en de lever niet significant 
veranderden in de tijd.  Er werd tevens geen significante toename gevonden in de 
expressie van Abcb1 en Abcg2 in lever- en darmweefsels, hetgeen niet in 
overeenstemming lijkt te zijn met eerder beschreven in vitro experimenten en klinisch 
onderzoek.  Het is mogelijk dat de muis geen optimaal model is voor het verder ontrafelen 
van de specifieke oorzaken van deze vorm van geneesmiddelresistentie tegen imatinib. 
Tot slot is in hoofdstuk 7 de rol onderzocht van 9 zogenaamde SNPs (single-
nucleotide polymorphisms) in 7 genen die betrokken zijn bij de eliminatie van 
geneesmiddelen in de farmacokinetiek van imatinib in 82 patiënten met GIST.  
Gebruikmakend van een in vitro modelsysteem werd aanvankelijk gevonden dat het 
Q141K polymorfisme in het ABCG2 gen leidt tot een significant verhoogde intracellulaire 
accumulatie van imatinib.  Echter, deze bevinding kon niet worden bevestigd in vivo.  
Significante correlaties werden tevens niet gevonden tussen polymorfismen in ABCB1, 
ABCG2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 of CYP3A5 en de orale klaring van 
imatinib. 
Het onderzoek beschreven in dit proefschrift had tot doel om factoren te 
identificeren die een rol spelen in de interindividuele farmacokinetische variabiliteit 
alsmede in de ontwikkeling van farmacokinetische resistentie bij de behandeling met 
imatinib.  Alhoewel het enzyme CYP3A4 een belangrijkste plaats inneemt in het 
metabolisme van imatinib kon genetische variabiliteit in dit gen niet positief gecorreleerd 
worden met farmacokinetische parameters op steady-state.  Bovendien kon worden 
aangetoond dat polymorfismen in de CYP3A4 en CYP3A5 genen niet fungeren als 
surrogaat voor de activiteit van de coderende eiwitten in kankerpatiënten, bepaald aan de 
hand van de klaring van het substraat midazolam. 
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Op basis van eerder gepubliceerd werk alsmede de alhier beschreven in vitro 
bevindingen was verondersteld dat ABCG2 een belangrijke rol zou kunnen spelen in de 
dispositie van imatinib.  Met name lag het voor de hand dat het variante Q141K allel 
geassocieerd zou zijn met een verhoogde blootstelling aan imatinib en dat autoinductie 
zou leiden tot verhoogde expressie van ABCG2, met dientengevolge een versnelde klaring 
in de tijd.  Echter, in preklinisch alsook retrospectief klinisch onderzoek konden deze 
hypotheses niet worden bevestigd. 
Het ligt voor de hand dat de interindividuele farmacokinetische variabiliteit niet 
verklaard kan worden aan de hand van slechts één enkel transporteiwit of één enzyme, 
maar dat vele factoren tesamen in ogenschouw genomen moeten worden.  Met betrekking 
tot de autoinductie van imatinib is het van belang zich te realiseren dat de muis 
waarschijnlijk geen bruikbaar model is voor verder onderzoek naar de mogelijke 
oorzaken van farmacokinetische resistentie.  Een prospectief klinisch onderzoek waarbij 
imatinib langdurig wordt toegediend aan patienten zal noodzakelijk zijn om verder 
inzicht te verwerven in dit proces.  Idealiter zou in een dergelijke studie tevens 
maandelijkse bloedbemonstering plaatsvinden voor het analyseren van steady-state 
concentraties van imatinib en de metaboliet CGP74588, die gevormd wordt vanuit 
imatinib via CYP3A4.  Vervolgstudies waarin de fenotypische activiteit van CYP3A4 wordt 
bepaald aan de hand van de midazolamklaring zouden eveneens een bijdrage kunnen 
leveren aan het verder ontrafelen van de specifieke rol van dit enzyme in de 
farmacokinetische variabiliteit na behandeling met imatinib, alsmede in een mogelijk 
veranderde klaring in de tijd.  Deze nieuw te vergaren informatie, tesamen met prospectief 
verzamelde gegevens aangaande farmacogenetica, kan dan geïncorporeerd worden in een 
zogenaamd populatie-farmacokinetisch model.  Met behulp van een dergelijk model kan 
kwantitatief de bijdrage bepaald worden van covariabelen in de interindividuele 
farmacokinetische variabiliteit.  Het verder verkennen en ontdekken van belangrijke 
covariabelen zal in de nabije toekomst resulteren in een beter voorspelbare en verlengde 
blootstelling van een tumor aan imatinib, en in een gunstiger behandelingsuitkomst. 
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